---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description. Covers Product description and Place of product in therapy. 302 evidence topics quoted from 115 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status

> “This presentation discusses potential future product candidates that are investigational only and have not yet been approved for marketing by the U.S. Food and Drug Administration.”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.1.1-2"></a>

##### Development phase: phase 3 portion of the pivotal phase 2/3 trial

> “In January 2026, we announced that 1500mg QW of ficerafusp alfa was selected as the optimal dose to bring forward in the Phase 3 portion of the FORTIFI-HN01 trial.”
> “In February 2026, the transition to the Phase 3 portion of the FORTIFI-HN01 trial was completed.”
> “We enrolled the first patients in Phase 2 of the FORTIFI-HN01 trial in February 2025.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.1-3"></a>

##### Breakthrough Therapy Designation and designated population

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.”
> “BTD was supported by results from multiple Phase 1/1b dose cohorts evaluating ficerafusp alfa in combination with pembrolizumab in patients with 1L HPV-negative R/M HNSCC.”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

<a id="topic-2.1.1-4"></a>

##### Other expedited program and orphan designations

> “In addition, we may seek fast-track designation for our potential product candidates in the future.”
> “We may not be able to obtain orphan drug designation for any indications for our product candidates, and we may not be able to maintain such designations if granted.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.1-5"></a>

##### FDA alignment on the accelerated approval pathway and confirmatory overall survival

> “As a result of our discussions with the FDA, we believe that ficerafusp alfa has a path to accelerated approval using an ORR-based interim endpoint with confirmatory approval based on an OS endpoint.”
> “We believe the trial can support an accelerated approval on the basis of overall response rate, or ORR, six-month durability, and qualitative OS.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.1-6"></a>

##### FDA alignment on the phase 3 dose

> “Bicara has aligned with the U.S. Food and Drug Administration (FDA) on a clear path to implement, by the end of the first quarter, the optimal dose for Phase 3 of FORTIFI-HN01”

Source: [Bicara Therapeutics phase 3 dose and 2026 outlook announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides)

<a id="topic-2.1.1-7"></a>

##### Regulatory status: Submission planned; BLA for accelerated approval to follow an interim analysis expected in mid-2027

> “In November 2026, we announced that FORTIFI-HN01 reached substantial enrollment to enable an interim analysis in mid-2027 to support a potential approval and U.S. launch in 2028.”
> “Consequently, we may be unable to successfully and efficiently execute and complete clinical trials that are required for Biologics License Application, or BLA, submission and FDA approval of ficerafusp alfa or any future product candidates or for similar applications to and approvals by foreign regulatory authorities.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

> “The primary endpoints are overall response rate based on RECIST v1.1 and overall survival, with results potentially supporting regulatory filings for both accelerated approval and full approval.”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

> “Expect topline results from an interim analysis of the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC in mid-2027.”

Source: [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)

<a id="topic-2.1.1-8"></a>

##### Launch: Anticipated in 2028

> “Interim analysis expected mid-2027 and potential U.S. launch in 2028”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.1.1-9"></a>

##### Alternate dosing study timed to the potential approval

> “We expect to have results from this study by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.1-10"></a>

##### Ongoing phase 1b cohorts outside the pivotal population

> “We are continuing to enroll a Phase 1b expansion cohort evaluating 1500mg QW of ficerafusp alfa in combination with pembrolizumab in patients with 1L R/M HPV-negative HNSCC with a CPS<1.”
> “We are continuing to enroll an additional Phase 1b expansion cohort evaluating 1500mg QW of ficerafusp alfa in combination with pembrolizumab in patients with HPV-positive R/M HNSCC and a history of heavy smoking.”
> “We are continuing to enroll Phase 1b expansion cohorts evaluating 1500mg QW of ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients”
> “with third-line metastatic colorectal cancer with microsatellite stable RAS/BRAF wild-type. We expect to present data from these cohorts in January 2027.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

> “we believe there is an opportunity to expand the development of ficerafusp alfa in combination with pembrolizumab to the approximately 20% of the R/M HNSCC that do not express PD-L1 and provide a chemotherapy-free alternative.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.1-11"></a>

##### Cutaneous squamous cell carcinoma and squamous cancer of the anal canal

> “In 2025, we presented data from additional Phase 1b cohorts evaluating ficerafusp alfa monotherapy in patients with second-line or later cutaneous squamous cell carcinoma, as well as ficerafusp alfa in combination with pembrolizumab in patients with second-line or later squamous cancer of the anal canal.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.1-12"></a>

##### Investigator-sponsored trials in head and neck cancer

> “In late 2025, we supported an investigator-sponsored trial to signal-seek in several areas in LA-HNSCC, including in the neoadjuvant setting.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “A Phase II Study of Ficerafusp Alfa (BCA 101) in Combination With Nivolumab in Platinum Refractory Head and Neck Squamous Cell Carcinoma Patients Who Progressed Within 6 Months After Multimodal Treatment for Locally Advanced Disease”

Source: [ClinicalTrials.gov NCT07529873](https://clinicaltrials.gov/study/NCT07529873)

> “Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Trial”

Source: [ClinicalTrials.gov NCT07465276](https://clinicaltrials.gov/study/NCT07465276)

> “Phase I/II Trial of Neoadjuvant Combination of Ficerafusp Alfa, Pembrolizumab, and SBRT for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)”

Source: [ClinicalTrials.gov NCT07552558](https://clinicaltrials.gov/study/NCT07552558)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Bicara Therapeutics

> “We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors.”
> “our lead program ficerafusp alfa, formerly BCA101, an investigational bifunctional epidermal growth factor receptor-, or EGFR, directed monoclonal antibody bound to a human transforming growth factor beta, or TGF-β, ligand trap.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.2.1-2"></a>

###### International nonproprietary name

> “ficerafuspum alfa”
> “chimeric immunoglobulin G1-kappa anti-(human epidermal growth factor receptor) fused at the C-terminus of both light chains, via a (G4S)3 peptide linker, to a fragment of the extracellular domain of human TGF-beta receptor type-2”

Source: [WHO Drug Information Recommended INN List 92 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl92.pdf)

<a id="topic-2.1.2.1-3"></a>

###### Development code and substance synonyms

| Registry field | Quoted record |
| --- | --- |
| Product name | “Ficerafusp Alfa” |
| Sponsor product code | “BCA101” |
| Substance synonym | “Bifunctional monoclonal antibody against epidermal growth factor receptor and transforming growth factor beta” |

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-2.1.2.1-4"></a>

###### Therapeutic class as described by the company

> “Ficerafusp alfa is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers.”
> “Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

<a id="topic-2.1.2.1-5"></a>

###### Brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational product form and route in the pivotal trial

| Registry field | Quoted record |
| --- | --- |
| Pharmaceutical form | “VIAL FOR INTRAVENOUS USE” |
| Route | “SOLUTION FOR INFUSION” |
| Active substance origin | “Protein - Other” |

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-2.1.2.2-2"></a>

###### Flat-dose intravenous administration in the phase 1b trial

> “Eligible patients received pembrolizumab 200 mg intravenously (IV) on day 1 and ficerafusp alfa 1,500 mg IV on days 1, 8, and 15 in 21-day cycles until disease progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of consent.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.2-3"></a>

###### Vial strength and commercial formulation

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO INN use statement

> “ficerafusp alfa chimeric immunoglobulin G1-kappa anti-(human epidermal growth factor receptor)”
> “extracellular domain fragment 23-159 (230-366 in the current sequence)”
> “produced in Chinese hamster ovary (CHO) cells, glycoform alfa antineoplastic”

Source: [WHO Drug Information Proposed INN List 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf)

<a id="topic-2.1.2.4-2"></a>

###### Registry intervention class

> “EGFR/TGFβ fusion monoclonal antibody”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-2.1.2.4-3"></a>

###### AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Population of the Breakthrough Therapy Designation

> “for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

<a id="topic-2.1.2.5-2"></a>

###### Indication pursued in the pivotal trial as described by the company

> “We are currently conducting a global, randomized, double-blind, Phase 2/3 FORTIFI-HN01 pivotal trial evaluating 1500mg dosed once weekly, or QW, of ficerafusp alfa in combination with pembrolizumab in first-line, or 1L, recurrent/metastatic, or R/M, human papillomavirus infection, or HPV, -negative head and neck squamous cell carcinoma, or HNSCC, whose tumors express programmed death-ligand 1 with combined positive score, or CPS, of ≥1.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.2.5-3"></a>

###### HPV testing limited to oropharyngeal primary tumors

> “An estimated 80% of cases of R/M HNSCC are HPV-negative, with testing for HPV status typically only being conducted in tumors originating from the oropharynx.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.5-4"></a>

###### Pivotal trial primary sites, HPV status, PD-L1 threshold, and prior therapy

> “Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.”
> “PD-L1 CPS ≥1.”
> “No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-2.1.2.5-5"></a>

###### HPV-negative disease as the only population enrolled

> “HPV-negative patients are a poorer-prognosis population in head and neck cancer, and the only population enrolled in”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Molecular structure: cetuximab-based anti-EGFR IgG1 antibody fused to the TGF-beta receptor II extracellular domain

> “Ficerafusp alfa is a bifunctional antibody that combines the well-established biologies of two targets”
> “the anti-EGFR antibody, cetuximab, fused to the extracellular domain of TGF-β receptor 2.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “Here, we developed BCA101, an anti-EGFR IgG1 mAb linked to an extracellular domain of human TGFβRII.”

Source: [Boreddy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10236157/)

> “Ficerafusp alfa is a novel bifunctional immunoglobulin G1 anti-EGFR antibody fused to the TGF-β receptor II ectodomain, which selectively neutralizes TGF-β in the TME.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.6.1-2"></a>

###### Tumor-directed TGF-beta ligand trap

> “Ficerafusp alfa was designed to use EGFR-binding to deliver potent anti-TGF-β therapy directly to EGFR-expressing tumors, potentially removing TGF-β and neutralizing its signaling activity”
> “We believe that localized TGF-β inhibition within the TME has the potential to increase its anti-tumor efficacy and durability, by remodeling the immunosuppressive and immune-excluded TME to enable the penetration of cytotoxic immune cells that drive deep and durable responses.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “Ficerafusp alfa (BCA101) is a first-in-class bifunctional antibody that fuses a TGF-β immune-modulating payload or trap to an EGFR tumor antigen–directed antibody for selective delivery to the tumor microenvironment. Ficerafusp alfa aims to target immunosuppressive mechanisms in the tumor microenvironment mediated by TGF-β1.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.6.1-3"></a>

###### Retained EGFR activity: inhibition of EGFR signaling and antibody-dependent cellular cytotoxicity

> “FaDu cells preincubated with either BCA101 or cetuximab and spiked with EGF showed comparable inhibition of EGFR phosphorylation (Tyr1068).”
> “BCA101 showed concentration-dependent ADCC activity in the reporter-based ADCC assay comparable with that of cetuximab (Fig. 2D)”

Source: [Boreddy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10236157/)

<a id="topic-2.1.2.6.1-4"></a>

###### TGF-beta isoform selectivity: TGF-beta1 and TGF-beta3 neutralized, TGF-beta2 spared

> “BCA101 could neutralize SMAD-mediated luciferase expression induced by TGFβ1 (Fig. 2F) and TGFβ3 (Supplementary Fig. S3A), and not neutralize TGFβ2 in HEK-SMAD reporter assay (Supplementary Fig. S3B).”

Source: [Boreddy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10236157/)

> “Ficerafusp alfa was specifically designed to spare the TGF-β2 isoform and avoid historical TGF-β-related toxicity.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.6.1-5"></a>

###### Preclinical immune effects and rationale for combination with PD-1 blockade

> “BCA101 increased production of proinflammatory cytokines and key markers associated with T-cell and natural killer–cell activation, while suppressing VEGF secretion. In addition, BCA101 inhibited differentiation of naïve CD4+ T cells to inducible regulatory T cells (iTreg) more strongly than the anti-EGFR antibody cetuximab.”
> “The combination of BCA101 and anti-PD1 antibody improved tumor inhibition in both B16-hEGFR–expressing syngeneic mouse models and in humanized HuNOG-EXL mice bearing human PC-3 xenografts.”

Source: [Boreddy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10236157/)

<a id="topic-2.1.2.6.1-6"></a>

###### Combination partner: pembrolizumab

> “Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical intratumoral TGF-beta neutralization and durable response in head and neck xenografts

> “TGFβ in tumors was neutralized by approximately 90% in animals dosed with 10 mg/kg of BCA101 compared with 54% in animals dosed with equimolar TGFβRII-Fc.”
> “In patient-derived xenograft mouse models of head and neck squamous cell carcinoma, BCA101 showed durable response after dose cessation.”

Source: [Boreddy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10236157/)

<a id="topic-2.1.2.6.2-2"></a>

###### Plasma TGF-beta1 neutralization by dose in the phase 1 dose escalation

> “Patients treated with ficerafusp alfa achieved complete and prolonged neutralization of TGF-β1 in plasma at weekly doses of ≥500 mg (Fig. 3A). Minimal neutralization of TGF-β2 was observed at doses of ≥500 mg (Fig. 3B). TGF-β3 levels were close to the lower limit of quantification and therefore not analyzed.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.6.2-3"></a>

###### EGFR target saturation inferred from exposure at doses of 500 mg or more

> “However, a dose-proportional increase in Cmax and AUC0–168h observed at doses ≥500 mg suggested that EGFR is likely fully saturated at this dose range.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.6.2-4"></a>

###### Plasma TGF-beta1 and tumor pSMAD2 in the 1500 mg weekly first-line HNSCC cohort

> “Complete and prolonged neutralization of TGF-β1 and minimal neutralization of TGF-β2 was observed in plasma after study treatment (Figs 4A and 4B).”
> “TGF-β–dependent pSMAD2 signaling was measured in paired tumor biopsies (baseline and cycle 2 day 1; n = 10). Significant downregulation of pSMAD2 (P < .05) was observed after treatment, particularly in HPV-negative tumors (Fig 4C).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.6.2-5"></a>

###### Tumor pSMAD2, CD8 T-cell infiltration, and circulating immune markers across the 750 mg, 1500 mg, and 2000 mg cohorts

> “Consistent with the observed clinical dose-response, biomarker analyses demonstrate a trend toward enhanced localized TGF-β pathway inhibition (measured via pSMAD2 reduction in tumor tissue) at the 1500 mg QW and 2000 mg Q2W dose levels”
> “Further supporting the sustained clinical benefit, this optimized target engagement is accompanied by the upregulation of key circulating immune markers (TNF-α, IFN-γ, CXCL9, and CXCL10), reflecting systemic immune activation at higher doses”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “Sustained TGF-β neutralization in plasma was observed across all dose groups”
> “Increased CD8 T cell tumor infiltration was observed in all dose groups, reaching statistical significance in the 1500 mg QW and 2000 mg Q2W dose groups”

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="topic-2.1.2.6.2-6"></a>

###### Company-reported biomarker comparison of 1500 mg and 750 mg weekly

> “In conjunction with the 2025 ESMO Asia Congress, we hosted a corporate call which included new biomarker data demonstrating that that 1500mg of ficerafusp alfa yielded a greater increase in TGF-β inhibition within the tumor microenvironment and greater immune activation, compared to 750mg of ficerafusp alfa.”
> “Updated biomarker results demonstrated that 2000mg Q2W maintains TGF-β inhibition and immune activation while delivering deep responses, consistent with the differentiated clinical profile established by 1500mg QW of ficerafusp alfa.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.6.2-7"></a>

###### Pembrolizumab exposure-response

> “There are no clinically significant exposure-response relationships for efficacy or safety at pembrolizumab dosages of 200 mg or 2 mg/kg every 3 weeks and 400 mg every 6 weeks regardless of cancer type”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Time to maximum concentration and half-life in the phase 1 dose escalation

> “Maximal concentrations (Cmax) were generally reached between 2 and 5 hours after the start of infusion on cycle 1 day 1. Thereafter, the concentration–time profiles declined in a biexponential manner at higher doses, with geometric mean half-life ranging from 14 hours for lower doses associated with target-mediated drug disposition to 84 hours for higher doses.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.6.3-2"></a>

###### Company-reported half-life of about eight days

> “The purpose of this expansion cohort was to further support the pharmacokinetic and pharmacodynamic profile of ficerafusp alfa, particularly its eight-day half-life, and the development of a less frequent dose regimen.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “Ficerafusp alfa’s half-life of ~ 8 days supports the rationale to explore less frequent dosing schedules”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### Dose proportionality and target-mediated drug disposition

> “Cmax and area under the plasma concentration versus time curve from 0 to 168 hours (AUC0–168h) increased in a slightly more than dose-proportional manner between 64 and 500 mg. However, a nearly dose-proportional increase in Cmax and AUC0–168h was observed between 500 and 1,500 mg. These data suggest that nonlinear clearance is negligible and linear clearance dominates at doses above 500 mg as EGFR is likely fully saturated.”
> “Of note, ficerafusp alfa showed a nonlinear PK profile consistent with target-mediated drug disposition at doses <500 mg. Specifically, nonoverlapping exposures were achieved at 750 and 1,500 mg once weekly dosages.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

> “PK analysis (data not shown) indicated that exposure increased in an approximately dose-proportional manner and all three dosing regimens maintained target therapeutic levels throughout treatment”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-2.1.2.6.3-4"></a>

###### Immunogenicity

> “Antidrug antibody incidence (as defined by Shankar and colleagues; ref. 26) ranged between 18% and 27% across all ficerafusp alfa doses in monotherapy and in combination with pembrolizumab.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.6.3-5"></a>

###### Nonclinical pharmacokinetics in cynomolgus monkeys

> “Following a single intravenous infusion of BCA101 to cynomolgus monkeys, serum mean maximum concentrations and mean exposures of the molecule increased dose proportionally (Supplementary Fig. S17), with no saturation of the routes of elimination. The observed volumes of distribution (33–74 mL/kg) suggest that BCA101 is well distributed to the tissues. Half-life of BCA101 ranged from 12.9 to 84.5 hours for the doses tested.”

Source: [Boreddy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10236157/)

<a id="topic-2.1.2.6.3-6"></a>

###### Dose-selection rationale for 1500 mg weekly

> “As a result, ficerafusp alfa 1,500 mg once weekly was selected as the recommended dosage based on the PK, pharmacodynamic, and preliminary antitumor activity observed at this dosage level and will continue to be assessed for safety and efficacy during dose expansion.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

> “The purpose of these two expansion cohorts was to inform dose selection for our pivotal study, consistent with the objectives of the FDA’s Project Optimus.”
> “The totality of the data suggests that a higher dose of ficerafusp alfa with greater TGF-β inhibition and immune activation drives deeper tumor responses that translate to more durable outcomes for patients. These data supported the selection of 1500mg QW of ficerafusp alfa as the optimal dose to advance into the Phase 3 portion of our FORTIFI-HN01 pivotal trial.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “The phase 2 objective was to determine the optimal biological dose (OBD) of ficerafusp alfa through an integrated analysis of safety, tolerability, PK, PD, and efficacy. Following OBD determination (1500 mg QW), the trial transitioned seamlessly into the phase 3 portion with 2:1 randomization (ficerafusp alfa:control).”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-2.1.2.6.3-7"></a>

###### Pharmacokinetic basis for less frequent dosing regimens

> “Based on available PK results from 1,500 to 1,750-mg every-2-week cohorts, the every-2-week dosing regimen is expected to reach non–clinically derived target concentrations (Supplementary Fig. S2A and S2B).”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

> “The growing body of pharmacokinetic, translational and clinical data and exposure-response modeling supports development of a less frequent dose regimen that is designed to optimize efficacy, safety and convenience without compromising the depth nor durability of response that are characteristic of ficerafusp alfa’s differentiated clinical profile.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.6.3-8"></a>

###### Pembrolizumab half-life and steady state

> “Steady-state concentrations of pembrolizumab were reached by 16 weeks of repeated dosing with an every 3-week regimen and the systemic accumulation was 2.1-fold.”
> “The terminal half-life (t1/2) is 22 days (32%).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pregnancy and breastfeeding: protocol exclusions

> “Pregnant or breastfeeding women.”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

> “Active pregnancy or breastfeeding.”
> “Women of childbearing potential (WOCBP) must have a negative blood highly sensitive serum pregnancy test within 7 days prior to receiving the first dose of study treatment.”
> “WOCBP should be willing to use highly effective contraception for birth control or be surgically sterile or abstain from heterosexual activity for the course of the study and are not permitted to donate oocytes during this time.”
> “Male participants must agree to use a condom or to remain abstinent (refrain from heterosexual intercourse), and to not donate sperm starting with the first dose of study treatment after the last dose of study medication.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-2.1.2.8-2"></a>

###### Hepatic and renal function: protocol requirements

> “Participant demonstrates adequate organ function, defined as follows:”
> “Creatinine clearance (CrCl) measured or calculated per institutional standards”
> “Total serum bilirubin ≤1.5 x× upper limit of normal (ULN)”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

> “Eligible study patients were age 18 years and older”
> “and adequate hepatic, renal, and hematologic function.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.8-3"></a>

###### Age of participants in the phase 1b 1500 mg cohort

> “Among treated patients (N = 42), median age was 63 years”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.8-4"></a>

###### Pembrolizumab label: pregnancy, lactation, and contraception

> “There are no available human data informing the risk of embryo-fetal toxicity.”
> “Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with KEYTRUDA and for 4 months after the last dose.”
> “Verify pregnancy status in females of reproductive potential prior to initiating KEYTRUDA”
> “Advise females of reproductive potential to use effective contraception during treatment with KEYTRUDA and for 4 months after the last dose.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Pembrolizumab label: older adults, renal impairment, and hepatic impairment

> “Of 3781 patients with melanoma, NSCLC, HNSCC, or urothelial carcinoma who were treated with KEYTRUDA in clinical studies, 48% were 65 years and over and 17% were 75 years and over. No overall differences in safety or effectiveness were observed between elderly patients and younger patients.”
> “The following factors had no clinically important effect on the CL of pembrolizumab: age (range: 15 to 94 years), sex, race (89% White), renal impairment”
> “mild to moderate hepatic impairment (total bilirubin ≤3 times ULN and any AST), or tumor burden. The impact of severe hepatic impairment (total bilirubin >3 times ULN and any AST) on the pharmacokinetics of pembrolizumab is unknown.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Ficerafusp alfa

<a id="topic-2.1.2.9.1-1"></a>

###### Ficerafusp alfa exposure with and without pembrolizumab

> “No significant difference in exposure was observed between ficerafusp alfa as monotherapy and in combination with pembrolizumab across 240 to 1,500 mg dosing.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.9.1-2"></a>

###### Protocol restrictions on systemic corticosteroids, immunosuppressants, and live vaccines

> “Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.”
> “Use of a live or live attenuated vaccine within 4 weeks prior to Screening. Note: Administration of killed, recombinant or inactivated vaccines is allowed.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-2.1.2.9.1-3"></a>

###### Concomitant anticoagulation

> “unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

> “Of note, this patient received prior palliative radiation to the primary tumor in the pancreas and was under treatment with rivaroxaban”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Ficerafusp alfa on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Toxicity of pembrolizumab when given with ficerafusp alfa

> “TRAEs were consistent with the mechanism of action and expected toxicity profiles of each treatment and the underlying disease pathology. No additive toxicity was observed.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

> “Based on the data available to date, there have been no synergistic toxicities with respect to immune-mediated AEs observed with ficerafusp alfa in combination with pembrolizumab.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.9.2-2"></a>

###### Effect on pembrolizumab pharmacokinetics or on cytochrome P450 substrates

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### FORTIFI-HN01 pivotal regimen

| Arm | Regimen |
| --- | --- |
| Phase 2 Arm A | “ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)” |
| Phase 2 Arm B | “ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W” |
| Phase 2 Arm C | “placebo QW + pembrolizumab 200 mg Q3W” |
| Phase 3 optimal biological dose arm | “ficerafusp alfa OBD + pembrolizumab 200 mg Q3W” |
| Phase 3 Arm C | “placebo QW + pembrolizumab 200 mg Q3W” |

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

> “Patients receive pembrolizumab (200 mg IV every 3 weeks for up to 35 cycles) and either ficerafusp alfa or placebo IV QW until disease progression or unacceptable toxicity.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

> “In January 2026, we announced that we selected 1500mg QW of ficerafusp alfa in combination with pembrolizumab as the optimal dose for Phase 3 portion of the FORTIFI-HN01 pivotal trial.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Doses studied in the phase 1b first-line HNSCC expansion cohorts

| Cohort | Ficerafusp alfa | Pembrolizumab |
| --- | --- | --- |
| 750 mg weekly | “Ficerafusp alfa 750 mg QW” | “Pembrolizumab 200 mg Q3W” |
| 1500 mg weekly | “Ficerafusp alfa 1500 mg QW” | “Pembrolizumab 200 mg Q3W” |
| 2000 mg every 2 weeks | “Ficerafusp alfa 2000 mg Q2W” | “Pembrolizumab 400 mg Q6W” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “Eligible patients received pembrolizumab 200 mg intravenously (IV) on day 1 and ficerafusp alfa 1,500 mg IV on days 1, 8, and 15 in 21-day cycles until disease progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of consent.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.10.1-3"></a>

###### Doses studied in the phase 1 dose escalation

> “At escalating doses in a parallel 3 + 3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa as monotherapy (64–1,500 mg) or in combination (240–1,500 mg) with pembrolizumab (200 mg i.v. every 3 weeks).”
> “The MTD was not reached in either cohort.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.10.1-4"></a>

###### Loading and every-3-week maintenance regimen under study in FORTIFI-FLEX

| Arm | Regimen |
| --- | --- |
| Arm A | “Loading phase (12 weeks): Ficerafusp alfa 1500 mg QW (standard dose) + pembrolizumab 200 mg Q3W.” “Maintenance phase: Ficerafusp alfa 2250 mg Q3W (alternative dose) + pembrolizumab 200 mg Q3W.” |
| Arm B | “Continuous ficerafusp alfa 1500 mg QW (standard dose) + pembrolizumab 200 mg Q3W.” |

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

> “In August 2026, we announced the initiation of FORTIFI-FLEX, a randomized clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg QW followed by maintenance dosing of 2250mg every three weeks as compared to 1500mg QW of ficerafusp alfa, each in combination with pembrolizumab.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.2.10.1-5"></a>

###### Dose modification rules in the phase 1b

> “Pembrolizumab was interrupted or discontinued (dose reduction not permitted) for grade ≥3 immune-related adverse events (AEs) per investigator assessment.”
> “Grade ≥3 AEs resulted in interruption, dose modification (ficerafusp alfa only), or permanent discontinuation according to study drug attribution.”
> “Patients who discontinued one study drug for any reason other than disease progression could continue the other per investigator discretion.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.10.1-6"></a>

###### Pembrolizumab labeled dosage for HNSCC

> “HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.”
> “Until disease progression, unacceptable toxicity, or up to 24 months”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Intravenous infusion over 120 minutes, with pembrolizumab given afterward

> “Ficerafusp alfa was administered as an infusion over 120 minutes.”
> “Pembrolizumab 200 mg i.v. was administered after ficerafusp alfa as a 30-minute infusion every 3 weeks (cycle length, 21 days).”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.10.2-2"></a>

###### Infusion-rate reduction for infusion-related reactions

> “The infusion rate of ficerafusp alfa was reduced by 50% for grade 1/2 or nonserious infusion-related reactions (IRRs); ficerafusp alfa was permanently discontinued for grade ≥3 or serious IRRs.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.10.2-3"></a>

###### Prophylaxis and premedication

> “Topical steroids and/or antibiotics were recommended as prophylaxis or treatment for acneiform dermatitis.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

> “Corticosteroid use as premedication for allergic reactions (e.g., intravenous contrast), or as a prophylactic management of AEs related to the therapies specified in the protocol is allowed.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-2.1.2.10.2-4"></a>

###### Pembrolizumab administration

> “Administer KEYTRUDA as an intravenous infusion over 30 minutes after dilution.”
> “Do not co-administer other drugs through the same infusion line.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Compassionate use and expanded access

> “Bicara does not currently offer an compassionate use/expanded access program for our investigational therapy, ficerafusp alfa.”
> “The safest and most appropriate way to access an investigational medicine is through participation in a clinical trial.”

Source: [Bicara Therapeutics expanded access policy](https://www.bicara.com/expanded-access-policy/)

<a id="topic-2.1.2.11-2"></a>

###### License from Biocon

> “On October 1, 2019, we entered into a Contract Transfer and License Agreement, or the Biocon Agreement, with Biocon Limited, or Biocon.”
> “Pursuant to the Biocon Agreement, we and Biocon agreed that Biocon would grant us a license, with the right to grant and authorize sublicenses to make, use, sell, offer to sell, import, and otherwise exploit certain fusion protein products of which ficerafusp alfa was the most advanced program.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

###### Manufacturing and supply

> “We have leveraged multiple third-party manufacturers to support the manufacturing of ficerafusp alfa for clinical trials and, if we receive regulatory approval, we intend to rely on such third parties for commercial manufacture.”
> “We currently obtain our supplies from third-party manufacturers on a purchase order basis and do not have any long-term supply agreements in place.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we primarily rely on WuXi Biologics (Hong Kong) Limited for the production of product necessary to complete our ongoing clinical trials.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.2.11-4"></a>

###### Commercial distribution arrangements and patient assistance

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Pembrolizumab regimen in the pivotal trial

> “Patients receive pembrolizumab (200 mg IV every 3 weeks for up to 35 cycles) and either ficerafusp alfa or placebo IV QW until disease progression or unacceptable toxicity.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-2.1.2.12-2"></a>

###### Pembrolizumab first-line HNSCC indications in the U.S. label

> “KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).”
> “KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.1.2.12-3"></a>

###### Pembrolizumab labeled dose for HNSCC

> “HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Pembrolizumab supply for the trials

> “Pursuant to the MSD Agreement, we provide ficerafusp alfa and MSD provides pembrolizumab to be used in combination in a clinical trial sponsored by us.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “This study was funded by Bicara Therapeutics Inc. with access to pembrolizumab in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="topic-2.1.2.12-5"></a>

###### Supportive therapy for acneiform dermatitis

> “Topical steroids and/or antibiotics were recommended as prophylaxis or treatment for acneiform dermatitis.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.12-6"></a>

###### Pembrolizumab label warnings that apply to the combination

> “Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously.”
> “Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment.”
> “KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% of 2799 patients receiving KEYTRUDA.”
> “Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody.”
> “Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Ficerafusp alfa on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Product-specific effects on healthcare quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Competing products named by the sponsor

> “We expect to compete with currently commercially available therapies for the treatment of HNSCC, including pembrolizumab (marketed as Keytruda by Merck & Co); the combination of pembrolizumab, platinum chemotherapy and 5-fluorouracil; and the combination of cetuximab (marketed as Erbitux by Eli Lilly & Company in the U.S. and by Merck KGaA outside of the U.S.), platinum chemotherapy and 5-fluorouracil.”
> “In addition, there are numerous companies that are developing new treatments for HNSCC, including but not limited to Akeso, Inc., AstraZeneca PLC, AVEO Pharmaceuticals, Inc., BioAtla Inc., BioNTech SE, Corbus Pharmaceuticals Holdings Inc., GSK plc, InhibRx Biosciences, Inc., Johnson & Johnson, Merus N.V. (a Genmab A/S company), PDS Biotechnology Corp, Pyxis Oncology, Inc., and Rakuten Medical, Inc.”
> “The key factors that will ultimately affect the success of our bifunctional therapies, if approved, are likely their safety, efficacy, convenience and cost.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

###### Ficerafusp alfa plus pembrolizumab: population definition and phase 1b HPV-negative results

> “granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

> “Twelve oropharyngeal tumors were classified as HPV-positive, whereas all oral cavity, hypopharynx, and larynx tumors were considered HPV-negative per current clinical standard.”
> “In efficacy-evaluable patients with HPV-negative (n = 28) or HPV-positive (n = 11) tumors, confirmed ORRs were 54% (complete response in 21%) and 27%, respectively. In the HPV-negative subgroup, median DOR was 21.7 months (95% CI, 6.0 to not estimable [NE]), median PFS was 9.9 months (95% CI, 4.4 to 22.7), and median OS was 21.3 months (95% CI, 9.9 to NE).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.14-3"></a>

###### Pembrolizumab-based regimens in HPV-negative disease: outcomes cited by the ficerafusp alfa phase 1b report

> “However, in retrospective real-world studies in the United States and the United Kingdom, median OS with pembrolizumab monotherapy in patients with HPV-negative tumors was approximately 9 months.”
> “In phase II studies assessing 1L treatment with anti–PD-1 agents (nivolumab or pembrolizumab) in combination with cetuximab (anti-EGFR) in all-comer R/M HNSCC populations, ORRs were 37% and 45%, respectively; median DOR with pembrolizumab plus cetuximab was 13.1 months, and median OS with nivolumab plus cetuximab in patients with HPV-negative tumors was 10.6 months.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.14-4"></a>

###### Pembrolizumab monotherapy: approved first-line indication

> “KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Pembrolizumab monotherapy: KEYNOTE-048 survival and response in the CPS 1 or greater population at 4-year follow-up

> “The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080)”
> “The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.1.2.14-6"></a>

###### Pembrolizumab plus platinum and fluorouracil: approved first-line indication

> “KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Pembrolizumab plus platinum and fluorouracil: KEYNOTE-048 survival and response at 4-year follow-up

> “The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population”
> “The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.1.2.14-8"></a>

###### KEYNOTE-048 population: HPV status and PD-L1 distribution

> “Eligible patients were age ≥ 18 years with previously untreated R/M squamous cell carcinoma of the oropharynx (known p16 expression), oral cavity, hypopharynx, or larynx, which was incurable by local therapy”
> “Random assignment was stratified by PD-L1 expression (tumor proportion score ≥ 50% v < 50%), p16 expression for oropharyngeal cancer (positive v negative), and Eastern Cooperative Oncology Group performance status (0 v 1).”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

> “Twenty-two percent of patients’ tumors were HPV-positive, 23% had PD-L1 TPS ≥50%, and 95% had Stage IV disease”
> “Eighty-five percent of patients’ tumors had PD-L1 expression of CPS ≥1 and 43% had CPS ≥20.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.1.2.14-9"></a>

###### Cetuximab plus platinum and fluorouracil (EXTREME): approved first-line indication and population

> “in combination with platinum-based therapy with fluorouracil for the first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN.”
> “Thirty-four percent of patients had oropharyngeal, 25% laryngeal, 20% oral cavity, and 14% hypopharyngeal primary tumors.”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Cetuximab plus platinum and fluorouracil (EXTREME): efficacy results

| Outcome | Result |
| --- | --- |
| Median overall survival, cetuximab with platinum-based therapy and fluorouracil (n=222), months | “10.1” |
| Median overall survival, platinum-based therapy and fluorouracil (n=220), months | “7.4” |
| Overall survival hazard ratio (95% CI) | “0.80 (0.64, 0.98)” |
| Median progression-free survival, cetuximab arm, months | “5.5” |
| Median progression-free survival, control arm, months | “3.3” |
| Objective response rate, cetuximab arm | “35.6%” |
| Objective response rate, control arm | “19.5%” |

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

###### Petosemtamab plus pembrolizumab: LiGeR-HN1 phase 3 topline results

> “Based on the first interim analysis assessed by an independent data monitoring committee (IDMC), treatment with the petosemtamab combination demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), reducing the risk of death by 50%, and objective response rate (ORR) versus pembrolizumab [OS: HR 0.50 (95% CI, 0.37, 0.67); p<0.0001; ORR: odds ratio 3.17 (95% CI, 2.06, 4.89; p<0.0001), meeting its dual primary endpoints, regardless of HPV status.”
> “LiGeR-HN1 (NCT06525220) is a randomized, open-label, global, multicenter Phase 3 study evaluating the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ HNSCC.”
> “The safety profile of petosemtamab when administered in combination with pembrolizumab was generally well tolerated and consistent with the previously reported safety profiles of the individual agents (petosemtamab and pembrolizumab).”

Source: [Genmab LiGeR-HN1 interim analysis announcement (2026)](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-statistically-significant-clinically-meaningful)

<a id="topic-2.1.2.14-12"></a>

###### Petosemtamab plus pembrolizumab: LiGeR-HN1 eligibility and HPV classification

> “The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.”
> “HNSCC patients eligible to receive pembrolizumab as 1L monotherapy with tumors expressing PD-L1, CPS ≥1.”
> “HNSCC patients should not have had previous systemic therapy administered in the incurable recurrent or metastatic setting”
> “Patient has a primary tumor site of nasopharynx, or sinonasal carcinoma (any histology)”

Source: [ClinicalTrials.gov NCT06525220](https://clinicaltrials.gov/study/NCT06525220)

> “p16 status is measured only in patients with oropharyngeal tumors; all other tumor locations are designated as p16 negative for the purposes of stratification.”
> “Randomization will be stratified based on p16 status (positive vs. negative) and PD-L1 CPS (<20 vs. ≥20), as determined by central laboratory testing, and ECOG PS (0 vs. 1).”

Source: [Machiels et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218485/)

<a id="topic-2.1.2.14-13"></a>

###### Petosemtamab plus pembrolizumab: phase 2 first-line cohort

> “In the 1L combination arm, treatment with petosemtamab plus pembrolizumab achieved a median overall survival (OS) of 28.2 months, associated with an overall response rate (ORR) of 63% and median progression free survival (mPFS) of 9.0 months in efficacy-evaluable patients (n=43), including a complete response (CR) rate of 19%.”
> “As of May 15, 2026, median duration of follow-up was 25.5 months; clinical activity was observed across combined positive PD L-1 expression levels and p16 subgroups.”
> “In the first-line combination arm, 45 patients were treated with 1500 mg of petosemtamab every two weeks plus 400 mg of pembrolizumab every six weeks until disease progression or unacceptable toxicity.”
> “Infusion-related reactions occurred in 38% of patients (7% Grade 3-4), and all resolved.”

Source: [Genmab petosemtamab phase 2 update announcement (2026)](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-updated-phase-2-data-demonstrating-more-two)

<a id="topic-2.1.2.14-14"></a>

###### Amivantamab plus pembrolizumab: OrigAMI-4 cohort 2, first-line, p16-positive oropharyngeal cancer excluded

> “Cohort 2 of the phase 1b/2 OrigAMI-4 (NCT06385080) study enrolled participants with previously untreated R/M HNSCC and PD-L1 combined positive score ≥1.”
> “Patients with p16-positive oropharyngeal cancer and prior anti-EGFR or anti-PD-(L)1 therapy were excluded.”
> “At a median follow-up of 13.6 months, confirmed ORR was 59% (95% CI, 42-74), with 7 (18%) complete responses.”
> “Median PFS was 7.7 months (95% CI, 5.0-NR); median OS was NR.”

Source: [Kao et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42742405/)

> “In Cohort 2 of the OrigAMI-4 study, treatment with subcutaneous amivantamab plus pembrolizumab, administered every three weeks, demonstrated a confirmed overall response rate of 56 percent (22/39; 95 percent confidence interval [CI], 40-72)”
> “At a median follow-up of 10.4 months (range, 1.6-12.5), 46 percent of patients remained on treatment.”

Source: [Johnson & Johnson OrigAMI-4 cohort 2 announcement (2026)](https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-immunotherapy-shows-strong-clinical-benefit-with-56-percent-overall-response-rate-in-first-line-recurrent-or-metastatic-head-and-neck-cancer)

<a id="topic-2.1.2.14-15"></a>

###### Amivantamab plus pembrolizumab and carboplatin: OrigAMI-4 cohort 5, first-line

> “Response rates were assessed separately in patients with HPV-associated OPSCC (n=7) and patients with all other forms of HNSCC (n=22), given known differences in how these patient populations respond to EGFR-targeted bispecifics.”
> “Among the 22 patients with forms of HNSCC other than HPV-associated OPSCC, the confirmed ORR was 77 percent (95 percent confidence interval [CI], 55-92), including complete responses in 14 percent and partial responses in 64 percent.”
> “Median overall survival was not reached, and 77 percent of patients were alive at one year. The remaining seven patients had HPV-associated OPSCC, with an ORR of 29 percent (95 percent CI, 4-71).”
> “Cohort 5 of the OrigAMI-4 study evaluated RYBREVANT FASPRO, administered every three weeks, in combination with pembrolizumab and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma receiving first-line treatment whose tumors tested positive for programmed death-ligand 1 (PD-L1), with a combined positive score (CPS) of 1 or greater.”

Source: [Johnson & Johnson OrigAMI-4 cohort 5 announcement (2026)](https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-advanced-head-and-neck-cancer)

<a id="topic-2.1.2.14-16"></a>

###### Amivantamab plus pembrolizumab and carboplatin: OrigAMI-5 phase 3 design and population

> “Have histologically or cytologically confirmed recurrent/metastatic (R/M) HNSCC that is considered incurable by local therapies: a. eligible primary tumor locations are the oral cavity, oropharynx, hypopharynx, or larynx; b. Must not have a primary tumor site of nasopharynx or primary tumor of unknown location”
> “Human papillomavirus (HPV) status must be known for participants with primary tumor location in oropharynx via p16 test, HPV DNA test, or high-risk HPV in situ hybridization (ISH). Any known p16, HPV DNA, or high-risk HPV ISH status of tumor must be negative”
> “Be treatment-naive for systemic therapy in the R/M setting”

Source: [ClinicalTrials.gov NCT07276399](https://clinicaltrials.gov/study/NCT07276399)

> “the ongoing Phase 3 OrigAMI-5 study (NCT07276399) assessing subcutaneous amivantamab with carboplatin and pembrolizumab as a first-line treatment in patients with HPV-unrelated recurrent or metastatic disease, regardless of PD-L1 expression”

Source: [Johnson & Johnson OrigAMI-4 cohort 2 announcement (2026)](https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-immunotherapy-shows-strong-clinical-benefit-with-56-percent-overall-response-rate-in-first-line-recurrent-or-metastatic-head-and-neck-cancer)

<a id="topic-2.1.2.14-17"></a>

###### Amivantamab and hyaluronidase: accelerated approval in previously treated disease

> “RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody.”
> “Limitations of use: RYBREVANT FASPRO is not indicated as a treatment for patients with oropharyngeal squamous cell carcinoma (OPSCC) that is human papillomavirus (HPV)-associated (i.e., by p16 IHC).”
> “This indication is approved under accelerated approval based on overall response rate and duration of response.”
> “The primary efficacy population included 102 patients with recurrent or metastatic HNSCC. Patients with HPV-associated OPSCC based on p16 testing results (only required for OPSCC), were excluded from the primary efficacy population.”

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

| Outcome | RYBREVANT FASPRO (N=102) |
| --- | --- |
| Overall response rate (95% CI) | “42% (32%, 52%)” |
| Complete response | “15%” |
| Partial response | “28%” |
| Patients with duration of response of 6 months or longer | “56%” |

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

<a id="topic-2.1.2.14-18"></a>

###### Enfortumab vedotin plus pembrolizumab: EV-202 first-line cohort

> “Eligible patients had R/M HNSCC, programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥1, and no prior systemic therapy in the R/M setting.”
> “The primary analysis included 41 patients.”
> “Sixteen patients achieved a response, and cORR was 39% [95% confidence interval (CI), 24.2–55.5]. The complete response rate was 9.8%.”
> “The median PFS was 5.1 months (95% CI, 3.5–not estimable).”
> “In patients with p16-positive oropharyngeal cancer ( n = 11), the cORR was 81.8%, in contrast to 23.3% in patients with non-HPV–associated disease ( n = 30).”
> “b For oropharyngeal squamous cell carcinoma only, patients without oropharyngeal cancer were considered HPV–negative.”
> “Patients also did not undergo any testing to confirm their HPV status.”

Source: [Swiecicki et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13473864/)

<a id="topic-2.1.2.14-19"></a>

###### HPV16-positive first-line combinations with pembrolizumab: BNT113

> “Patients who present histologically confirmed recurrent or metastatic HPV16+ HNSCC that is considered incurable by local therapies.”
> “Patients must not have had prior systemic anticancer therapy administered in the incurable recurrent or metastatic setting.”

Source: [ClinicalTrials.gov NCT04534205](https://clinicaltrials.gov/study/NCT04534205)

<a id="topic-2.1.2.14-20"></a>

###### HPV16-positive first-line combinations with pembrolizumab: PDS0101

> “HPV16 tumor positivity (central testing).”
> “Tumor PD-L1 expression defined as a CPS ≥ 1 using the FDA- approved pembrolizumab (KEYTRUDA®) assay (local testing).”
> “The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigational product, PDS0101, nor the conduct of the study.”

Source: [ClinicalTrials.gov NCT06790966](https://clinicaltrials.gov/study/NCT06790966)

<a id="topic-2.1.2.14-21"></a>

###### HPV-negative disease after PD-1 inhibitor and platinum: ficlatuzumab plus cetuximab

> “Participants with oropharyngeal cancer will be required to have proof of p16 negative status submitted on the basis of a pathology report”
> “Participants must have failed prior therapy with an anti-PD-1/PD-L1 ICI and with platinum-based chemotherapy administered in combination or sequentially, in either the locally advanced or R/M setting.”

Source: [ClinicalTrials.gov NCT06064877](https://clinicaltrials.gov/study/NCT06064877)

Additional sources: [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/); [Vermorken et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18784101/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition of head and neck squamous cell carcinoma and its HPV-negative and HPV-positive forms

> “Most head and neck cancers are derived from the mucosal epithelium in the oral cavity, pharynx and larynx and are known collectively as head and neck squamous cell carcinoma (HNSCC).”
> “Oral cavity and larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16. Thus, HNSCC can be separated into HPV-negative or HPV-positive HNSCC.”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.1-2"></a>

###### Primary sites of HPV-negative disease

> “Although human papillomavirus (HPV)–positive HNSCC primarily occurs in the oropharynx and is associated with high cure rates, most tumors arising in other sites (oral cavity, larynx, and hypopharynx) are HPV-negative.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.1.1-3"></a>

###### Tobacco and alcohol as the principal causes of HPV-negative disease

> “People who use both tobacco and alcohol are at greater risk of developing these cancers than people who use either tobacco or alcohol alone”
> “Most head and neck squamous cell carcinomas of the mouth and voice box are caused by tobacco and alcohol use”

Source: [National Cancer Institute (2021)](https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet)

> “HPV-positive OPSCCs have risk factors related to sexual behavior whereas HPV-negative cancers are strongly associated with tobacco and alcohol use.”

Source: [Chaturvedi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3221528/)

<a id="topic-2.2.1.1-4"></a>

###### Combined tobacco and alcohol exposure, all oral cavity and pharynx cancer

> “Known risk factors include any form of tobacco use and alcohol consumption, with a 30-fold increased risk for individuals who both smoke and drink heavily.”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.1-5"></a>

###### Combined tobacco and alcohol exposure and other environmental risk factors, all HNSCC

> “Tobacco and alcohol consumption are the high-risk factors that occur most widely geographically. Of note, heavy users of both substances have >35-fold higher risk of developing HNSCC”
> “In general, the high male:female ratios for HPV-negative HNSCC incidence reflect the sex-specific patterns of modifiable risk behaviours, including the use of the aforementioned tobacco, smokeless tobacco, areca nut, betel quid and alcohol”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.1-6"></a>

###### HPV as a cause confined to the oropharynx

> “About three-quarters of all oropharyngeal cancers are caused by chronic HPV infection”
> “Although HPV can be detected in other head and neck cancers, it appears to be the cause of cancer formation only in the oropharynx.”

Source: [National Cancer Institute (2021)](https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of HPV-negative head and neck squamous cell carcinoma

<a id="topic-2.2.1.2.1-1"></a>

###### Estimated U.S. new cases in 2026, all oral cavity and pharynx cancer

> “In 2026, an estimated 60,480 new cases of cancer of the oral cavity (mouth) and pharynx (throat) will be diagnosed in the US”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.2.1-2"></a>

###### Estimated U.S. new cases in 2026 by subsite, all oral cavity, pharynx, and laryngeal cancer

| Site | Estimated new cases, both sexes | Male | Female |
| --- | --- | --- | --- |
| Oral cavity and pharynx, total | “60,480” | “43,070” | “17,410” |
| Tongue | “20,420” | “14,250” | “6170” |
| Mouth | “15,810” | “9230” | “6580” |
| Pharynx | “21,760” | “17,880” | “3880” |
| Other oral cavity | “2490” | “1710” | “780” |
| Larynx | “12,290” | “9730” | “2560” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.2.1-3"></a>

###### U.S. incidence rate, all oral cavity and pharynx cancer

> “The rate of new cases of oral cavity and pharynx cancer was 11.7 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

<a id="topic-2.2.1.2.1-4"></a>

###### U.S. incidence rate, all laryngeal cancer

> “The rate of new cases of laryngeal cancer was 2.5 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-2.2.1.2.1-5"></a>

###### U.S. incidence trends, all oral cavity and pharynx cancer

> “Incidence rates increased by 0.7% per year during 2013 to 2022, mostly driven by cancers associated with human papillomavirus (HPV) that occur in the oropharynx (the part of the throat behind the oral cavity that includes the back one-third of the tongue, soft palate, and tonsils), which increased by about 2% per year versus a decrease of 1% per year for other oral sites.”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.2.1-6"></a>

###### U.S. incidence trend of HPV-negative oropharyngeal cancer

> “Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to 242%) from 1988 to 2004 (from 0.8 per 100,000 to 2.6 per 100,000), and incidence for HPV-negative cancers declined by 50% (95% CI, 47% to 53%; from 2.0 per 100,000 to 1.0 per 100,000).”

Source: [Chaturvedi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3221528/)

<a id="topic-2.2.1.2.1-7"></a>

###### HPV-negative share of U.S. oropharyngeal squamous cell carcinoma

| Oropharynx, United States, 2012 to 2016 | Quoted value |
| --- | --- |
| Average annual reported cases | “19,000” |
| Attributable to 9vHPV-targeted types, number (%) | “12,600 (66)” |
| Attributable to other HPV types, number (%) | “900 (5)” |
| HPV-negative, number (%) | “5,500 (29)” |

Source: [Senkomago et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6705893/)

<a id="topic-2.2.1.2.1-8"></a>

###### HPV-positive share in a first-line recurrent or metastatic HNSCC trial population

> “Twenty-two percent of patients’ tumors were HPV-positive”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.1.2.1-9"></a>

###### HPV status among U.S. real-world first-line pembrolizumab recipients with recurrent or metastatic HNSCC

| HPV status, all subtypes | All patients, n (%) | Pembrolizumab monotherapy, n (%) | Pembrolizumab plus chemotherapy, n (%) |
| --- | --- | --- | --- |
| Positive | “233 (36.1)” | “163 (37.8)” | “70 (32.6)” |
| Negative | “258 (39.9)” | “165 (38.3)” | “93 (43.3)” |
| Equivocal or unknown | “155 (24.0)” | “103 (24.9)” | “52 (24.2)” |

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

<a id="topic-2.2.1.2.1-10"></a>

###### Company-stated HPV-negative share of recurrent or metastatic HNSCC

> “Approximately 80% of patients with R/M HNSCC are HPV-negative.”

Source: [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)

<a id="topic-2.2.1.2.1-11"></a>

###### Median age at diagnosis by etiology, all HNSCC

> “HNSCC is a cancer of adults, with a median age at diagnosis of 66 years for HPV-negative HNSCC, 53 years for HPV-positive HNSCC and 50 years for EBV-positive HNSCC”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.2.1-12"></a>

###### Global new cases in 2024 by subsite, all histologies

| GLOBOCAN 2024 cancer site | New cases | Percentage of all cases |
| --- | --- | --- |
| Lip, oral cavity | “452,205” | “2.2” |
| Larynx | “193,937” | “0.9” |
| Oropharynx | “107,887” | “0.5” |
| Hypopharynx | “91,464” | “0.4” |

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.2.1-13"></a>

###### Metastatic disease at diagnosis and recurrence after initial therapy, all HNSCC

> “Ten percent of patients have metastatic disease at diagnosis, and approximately 50% of those with locally advanced HNSCC have recurrence or metastasis after initial therapy.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.1.2.1-14"></a>

###### Recurrence after primary treatment of locoregionally advanced HNSCC in U.S. adults aged 66 years or older

> “In the resected cohort, 333 patients (66%) experienced recurrence following their primary treatment, compared with 169 (34%) who remained recurrence-free throughout the follow-up period. In the unresected cohort, 791 patients (65%) developed recurrence and 426 did not (35%)”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-2.2.1.2.1-15"></a>

###### Company-stated metastasis and recurrence rates, all HNSCC

> “Ten percent of HNSCC patients are diagnosed with metastatic disease and up to 30% develop a recurrence or metastases over time after receiving initial treatment for advanced HNSCC.”

Source: [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of HPV-negative head and neck squamous cell carcinoma

<a id="topic-2.2.1.2.2-1"></a>

###### U.S. prevalence in 2023, all oral cavity and pharynx cancer

> “In 2023, there were an estimated 461,008 people living with oral cavity and pharynx cancer in the United States.”

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

<a id="topic-2.2.1.2.2-2"></a>

###### U.S. prevalence in 2023, all laryngeal cancer

> “In 2023, there were an estimated 87,355 people living with laryngeal cancer in the United States.”

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-2.2.1.2.2-3"></a>

###### Prevalence of HPV-negative or recurrent or metastatic disease

No evidence found.

<a id="topic-2.2.1.2.2-4"></a>

###### PD-L1 combined positive score distribution in a first-line recurrent or metastatic HNSCC trial population

> “In total, 128 (14.5%) participants had PD-L1 CPS < 1, 373 (42.3%) had CPS 1-19, and 381 (43.2%) had CPS ≥ 20.”

Source: [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

> “Eighty-five percent of patients’ tumors had PD-L1 expression of CPS ≥1 and 43% had CPS ≥20.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.1.2.2-5"></a>

###### PD-L1 combined positive score distribution among U.S. real-world first-line pembrolizumab recipients

> “A CPS of <1 was recorded for 10.2% of this latter group, while 83.8% had a score of ≥1 and 42.3% had a score of ≥20.”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Stage at diagnosis and five-year relative survival, all oral cavity and pharynx cancer

| SEER stage | Percent of cases | Five-year relative survival |
| --- | --- | --- |
| Localized | “26%” | “88.7%” |
| Regional | “55%” | “69.7%” |
| Distant | “12%” | “36.0%” |
| Unstaged | “6%” | “62.3%” |

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

> “5-Year Relative Survival 69.9%”

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

<a id="topic-2.2.1.3-2"></a>

###### Stage at diagnosis and five-year relative survival, all laryngeal cancer

| SEER stage | Percent of cases | Five-year relative survival |
| --- | --- | --- |
| Localized | “49%” | “79.8%” |
| Regional | “30%” | “49.4%” |
| Distant | “15%” | “36.0%” |
| Unstaged | “6%” | “57.0%” |

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

> “5-Year Relative Survival 62.5%”

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-2.2.1.3-3"></a>

###### Estimated U.S. deaths in 2026 and death rate, all oral cavity and pharynx cancer

> “The death rate was 2.7 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

> “13,150 people will die from the disease”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.3-4"></a>

###### Estimated U.S. deaths in 2026 and death rate, all laryngeal cancer

| Measure | Quoted value |
| --- | --- |
| Estimated deaths in 2026 | “3,960” |

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

> “The death rate was 0.9 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-2.2.1.3-5"></a>

###### U.S. mortality trends, all oral cavity and pharynx cancer

> “After decades of decline, the mortality rate for cancers of the oral cavity and pharynx combined increased by 0.8% per year from 2009 through 2023, driven by an increase of about 2% per year in deaths from cancers of the tongue, tonsil, and oropharynx, most of which are associated with HPV.”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.3-6"></a>

###### Survival trend attributed to the changing share of smoking-related cancers, all oral cavity cancer

> “For example, the increase in survival for people diagnosed with oral cavity cancers from 58% in the mid‐1990s to 69% in 2015–2021 partly reflects a decreased proportion of smoking‐related cancers and an increased proportion of HPV infection‐associated cancers, which typically have a better prognosis.”

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.3-7"></a>

###### Global deaths in 2024 by subsite, all histologies

| GLOBOCAN 2024 cancer site | Deaths | Percentage of all deaths |
| --- | --- | --- |
| Lip, oral cavity | “194,108” | “2.0” |
| Larynx | “96,619” | “1.0” |
| Oropharynx | “51,823” | “0.5” |
| Hypopharynx | “49,748” | “0.5” |

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.3-8"></a>

###### HPV-negative versus HPV-positive survival, locally advanced oropharyngeal cancer treated with chemoradiotherapy

> “The 3-year rates of overall survival were 82.4% (95% CI, 77.2 to 87.6) in the HPV-positive subgroup and 57.1% (95% CI, 48.1 to 66.1) in the HPV-negative subgroup”

Source: [Ang et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2943767/)

<a id="topic-2.2.1.3-9"></a>

###### HPV-negative versus HPV-positive survival, population-based U.S. oropharyngeal cancer

> “Median survival was significantly longer for HPV-positive than for HPV-negative patients (131 v 20 months; log-rank P < .001; adjusted hazard ratio, 0.31; 95% CI, 0.21 to 0.46). Survival significantly increased across calendar periods for HPV-positive (P = .003) but not for HPV-negative patients (P = .18).”

Source: [Chaturvedi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3221528/)

<a id="topic-2.2.1.3-10"></a>

###### Survival after recurrence of locoregionally advanced HNSCC in U.S. adults aged 66 years or older

> “Within the resected cohort, patients with recurrence had a median OS of 23.8 months vs 44.4 months for patients without recurrence (P = 0.008); the 5-year OS rate was 30.2% compared with 42.5%, respectively”
> “Similarly, in the unresected cohort, the median OS was 23.7 months for patients with recurrence compared with 64.5 months for those without (P < 0.001), and the 5-year OS rate was 30.6% compared with 50.8%, respectively”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-2.2.1.3-11"></a>

###### Median overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC at 4-year follow-up

> “The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).”
> “The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population (HR, 0.71; 95% CI, 0.59 to 0.85; nominal one-sided P = .00008; Figs 2D-2F).”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.1.3-12"></a>

###### Five-year overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC

> “The 5-year OS rate in the total population was 14.4 % for pembrolizumab versus 6.5 % for EXTREME and 16.0 % for pembrolizumab-chemotherapy versus 5.2 % for EXTREME.”

Source: [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/)

<a id="topic-2.2.1.3-13"></a>

###### Real-world overall survival with first-line pembrolizumab by HPV status in recurrent or metastatic HNSCC

> “Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors”
> “Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

Additional sources: [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### EGFR overexpression, all HNSCC

> “EGFR is overexpressed in 80–90% of HNSCC tumours and is associated with poor overall survival (OS) and progression-free survival (PFS)”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.4-2"></a>

###### Genomic alterations of HPV-negative tumors

> “HPV-negative tumours are enriched for CDKN2A and TP53 alterations, frequent focal deletions in other TSGs (such as NSD1, FAT1, NOTCH1 and SMAD4) and frequent focal amplification of the genes encoding the receptor tyrosine kinases EGFR, HER2 (also known as ERBB2) and FGFR1”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

> “Smoking-related HNSCCs demonstrate near universal loss-of-function TP53 mutations and CDKN2A inactivation with frequent copy number alterations including amplification of 3q26/28 and 11q13/22.”

Source: [Cancer Genome Atlas Network (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4311405/)

<a id="topic-2.2.1.4-3"></a>

###### Field cancerization in HPV-negative disease

> “Rather, HPV-negative HNSCC arises from the grossly normal upper aerodigestive mucosa subject to ‘epithelial field cancerization’, where chronic exposure to carcinogens has resulted in molecular changes preconditioning towards malignant progression”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.4-4"></a>

###### EGFR, TGF-beta, and immune exclusion in HPV-negative disease

> “HPV-negative disease is often aggressive and is characterized by epidermal growth factor receptor (EGFR) overexpression, transforming growth factor-β (TGF-β) signaling, and poor tumor penetration of immune cells in the tumor microenvironment (TME), resulting in markedly worse survival.”
> “TGF-β–driven epithelial-mesenchymal transition and extracellular matrix dysregulation create a fibrotic TME that limits tumor penetration, promoting resistance to anti-EGFR and anti–PD-1 therapy.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.1.4-5"></a>

###### Immune infiltration by HPV status

> “We found that HPV-positive tumors were much more strongly immune infiltrated compared with HPV-negative tumors”

Source: [Mandal et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5070962/)

<a id="topic-2.2.1.4-6"></a>

###### TGF-beta in immune evasion and resistance to EGFR antibodies

> “Factors in the HNSCC TME, including IL-10 and TGFβ, also promote macrophage polarization to the immunosuppressive M2 phenotype”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

> “Specifically, it has been shown that elevated levels of TGF-β in the TME are associated with immune evasion and resistance to cetuximab therapy”
> “TGF-β can also induce EMT through its transactivation of EGFR, synergistically leading to increased tumor invasion and therapy resistance”

Source: [Britton et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11394608/)

<a id="topic-2.2.1.4-7"></a>

###### TGF-beta-mediated resistance to cetuximab in preclinical models

> “Therefore, elevated levels of TGF-β in the tumor microenvironment enable tumor cells to evade ADCC and resist the antitumor activity of cetuximab”

Source: [Bedi et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3640459/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Histopathologic diagnosis

> “The diagnosis of HNSCC can usually be made on the basis of routine histopathology with haemotoxylin and eosin staining.”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.5-2"></a>

###### College of American Pathologists 2025 guideline update

> “Seven strong recommendations, 4 conditional recommendations, and 5 good practice statements are offered in the guideline update.”

Source: [Lewis et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40126379/)

<a id="topic-2.2.1.5-3"></a>

###### HPV testing of oropharyngeal carcinoma by p16 immunohistochemistry

> “Recommendation 2. For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC. In certain scenarios HPV-specific testing should be performed: (1) in geographic regions with a low prevalence of HR-HPV–associated OPSCC; (2) when p16 IHC is equivocal (50%–70% staining or when staining is extensive but weak); (3) when there is a discrepancy between p16 IHC and morphology; (4) for large, multisite tumors overlapping the oropharynx; (5) when specimens are from a non-tonsillar, non–base of tongue oropharyngeal site; and (6) when required by clinical trials.”
> “For an OPSCC with classic characteristics, p16 IHC remains the optimal option for HR-HPV testing.”

Source: [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

<a id="topic-2.2.1.5-4"></a>

###### No routine HPV testing of oral cavity, laryngeal, and hypopharyngeal carcinoma

> “Recommendation 8. Pathologists should not routinely perform HR-HPV testing on patients with primary oral cavity, laryngeal, nasopharyngeal, or hypopharyngeal SCCs of the head and neck for prognostic purposes.”
> “Unlike the oropharynx, identifying HPV in primary oral cavity, laryngeal, and hypopharyngeal SCCs does not have clear and consistent implications for patient prognosis or patient management”

Source: [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

<a id="topic-2.2.1.5-5"></a>

###### HPV-specific test methods

> “Recommendation 12. For HPV-specific testing, pathologists should use tests that exhibit optimal performance characteristics—such as RNA-ISH or DNA PCR—and have adequate coverage of non–HPV 16 high-risk types. DNA-ISH is not recommended.”

Source: [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

<a id="topic-2.2.1.5-6"></a>

###### FDA-approved PD-L1 companion diagnostic for pembrolizumab in HNSCC

| Field | Quoted entry |
| --- | --- |
| Diagnostic name | “PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)” |
| Indication and specimen | “Head and Neck Squamous Cell Carcinoma (HNSCC) - Tissue” |
| Drug | “Keytruda (pembrolizumab) BLA 125514” |
| Biomarker | “PD-L1 protein expression [Combined Positive Score (CPS) ≥ 1]” |
| Approval | “P150013/S014 (06/10/2019)” |

Source: [FDA List of Cleared or Approved Companion Diagnostic Devices (2026)](https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools)

<a id="topic-2.2.1.5-7"></a>

###### PD-L1 and p16 assessment in the first-line pembrolizumab registration trial

> “Randomization was stratified by tumor PD-L1 expression (TPS ≥50% or <50%) according to the PD-L1 IHC 22C3 pharmDx assay, HPV status according to p16 IHC (positive or negative), and ECOG PS (0 vs. 1).”
> “A retrospective re-classification of patients’ tumor PD-L1 status according to CPS using the PD-L1 IHC 22C3 pharmDx assay was conducted using the tumor specimens used for randomization.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.1.5-8"></a>

###### PD-L1 testing patterns in U.S. recurrent or metastatic HNSCC

> “Of 2,207 patients, 32.7 % received PD-L1 testing before 1L therapy initiation, 17.4 % after 1L therapy initiation, and 50.0 % were never tested.”

Source: [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/)

> “Evidence of PD-L1 testing of any kind was identified for 71.7% of the study population, and a CPS test result was available for 352 individuals (54.5%).”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

Additional sources: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### General symptoms: neck mass, nonhealing sore, dysphagia, and voice change

> “Head and neck cancer symptoms may include a lump in the neck or a sore in the mouth or the throat that does not heal and may be painful, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice.”

Source: [National Cancer Institute (2021)](https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet)

> “Symptoms may include a sore in the throat or mouth that bleeds easily and does not heal; a persistent red or white patch, lump, or thickening in the throat or mouth; ear pain; a neck mass; or coughing up blood. Difficulty chewing, swallowing, or moving the tongue or jaw are often later symptoms.”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.6-2"></a>

###### Oral cavity tumors: nonhealing ulcer and impaired chewing and speech

> “Cancers of the oral cavity, including the mobile tongue, floor of mouth, buccal mucosa, alveolar ridges, retromolar trigone and hard palate, classically present with a non-healing mouth sore or ulcer. Oral cavity tumours are often diagnosed at an early stage due to the patient’s self-identification of the mass lesion and symptoms that interfere with the fundamental functions of eating and speaking, such as pain with chewing or dysarthria (difficulty speaking).”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.6-3"></a>

###### Pharyngeal tumors: dysphagia, odynophagia, and otalgia

> “Primary tumours of the oropharynx, including the base of the tongue, the palatine tonsils, the soft palate and the hypopharynx, typically become symptomatic at a later stage, owing to their hidden anatomical location. When present, symptoms such as dysphagia (difficulty eating), odynophagia (pain when swallowing) or otalgia (ear pain) often herald a more advanced tumour.”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.6-4"></a>

###### Laryngeal tumors: hoarseness and airway obstruction

> “Patients with cancers of the larynx frequently present with voice changes or florid hoarseness, resulting in diagnosis at an early stage. If tumours are neglected, patients can present with dyspnea (difficulty breathing) and, ultimately, airway obstruction, prompting tracheostomy.”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.6-5"></a>

###### Site-specific symptoms: oral cavity, pharynx, and larynx

> “Oral cavity. A white or red patch on the gums, the tongue, or the lining of the mouth; a growth or swelling of the jaw that causes dentures to fit poorly or become uncomfortable; and unusual bleeding or pain in the mouth. Throat (pharynx). Pain when swallowing; pain in the neck or the throat that does not go away; pain or ringing in the ears; or trouble hearing. Voice box (larynx). Trouble breathing or speaking, pain when swallowing or ear pain.”

Source: [National Cancer Institute (2021)](https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet)

<a id="topic-2.2.1.6-6"></a>

###### Recurrent HPV-negative disease: bleeding, pain, dysphagia, and cachexia (company-stated)

> “These HPV-negative tumors often exhibit a recurrence pattern that is primarily local and are associated with severe morbidities, including fatal tumor bleeding, intense pain, difficulty swallowing, significant weight loss, and cachexia.”

Source: [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)

Additional sources: [Mody et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34562395/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Severe late toxicity after concurrent chemoradiotherapy

> “Severe late toxicity was defined in this secondary analysis as chronic grade 3 to 4 pharyngeal/laryngeal toxicity (RTOG/European Organisation for the Research and Treatment of Cancer late toxicity scoring system) and/or requirement for a feeding tube ≥ 2 years after registration and/or potential treatment-related death (eg, pneumonia) within 3 years.”
> “A total of 230 patients were assessable for this analysis: 99 patients with severe late toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity.”

Source: [Machtay et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4911537/)

<a id="topic-2.2.1.7-2"></a>

###### Swallowing, speech, and voice impairment in survivors

> “Swallowing and speech impairments occur in ~50% of HNSCC survivors following radiotherapy treatment and are often present long-term”
> “For example, a majority (68%) of HNSCC survivors reported voice problems even 10 years after radiotherapy”
> “Furthermore, the two-year prevalence of dysphagia is 45% among HNSCC survivors (all therapies) and is 4–8 times more likely to occur in these individuals than in those who never had cancer”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.7-3"></a>

###### Chronic dysphagia and aspiration after combined modality therapy

> “Combined modality therapy is associated with substantial acute and late toxicities, including chronic dysphagia with a risk of aspiration pneumonia, and possibly increased non-cancer mortality”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.7-4"></a>

###### Lymphedema and other long-term effects of surgery and radiotherapy

> “However, if lymph nodes are removed, the flow of lymph in the area where they were removed may be slower and lymph could collect in the tissues (a condition called lymphedema), causing additional swelling that may last for a long time.”
> “Although side effects will improve slowly over time in many patients, others will experience long-term side effects of surgery or radiation therapy, including difficulty swallowing, speech impairment, and skin changes”

Source: [National Cancer Institute (2021)](https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet)

<a id="topic-2.2.1.7-5"></a>

###### Second primary tumors after HPV-negative disease

> “As such, patients with a first HPV-negative HNSCC are at high risk for a SPT of the upper aerodigestive tract, including in the head and neck, oesophagus or lung”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.7-6"></a>

###### Suicide among survivors

> “In addition to deaths directly caused by HNSCC, survivors of this cancer have the second highest rate of suicide (63.4 cases per 100,000 individuals) after those with pancreatic cancer (86.4 cases per 100,000 individuals), compared with survivors of other cancers (23.6 cases per 100,000 individuals).”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of HPV-negative head and neck squamous cell carcinoma

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### KEYNOTE-048 health-related quality of life instruments and endpoints

> “HRQoL was measured using the European Organisation for Research and Treatment of Cancer 30-question quality-of-life (EORTC QLQ-C30), the EORTC 35-question quality-of-life head and neck cancer-specific module (EORTC QLQ-H&N35), and the EuroQol 5-dimension 3-level instruments (EQ-5D-3L).”
> “Secondary endpoints included mean change from baseline in EORTC QLQ-C30 global health status/quality of life (GHS/QoL) at week 15 and time to deterioration (TTD) in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing.”

Source: [Rischin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35381576/)

<a id="topic-2.2.1.8.1-2"></a>

###### KEYNOTE-048 global health status at week 15 and time to deterioration

> “Of 882 enrolled participants, 844 received ≥ 1 dose of study treatment and completed ≥ 1 HRQoL assessment; adherence was ≥ 79% at week 15 across treatment groups.”
> “At week 15, EORTC QLQ-C30 GHS/QoL scores remained stable; no clinically meaningful between-group differences were observed (least squares mean difference, pembrolizumab vs cetuximab-chemotherapy, 0.24; 95% CI, -3.34 to 3.82; pembrolizumab-chemotherapy vs cetuximab-chemotherapy, 0.40; 95% CI, -3.46 to 4.26).”
> “Median TTD in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing scores was not reached over 51 weeks across groups, showing stable HRQoL.”
> “TTD was similar between groups for EORTC QLQ-C30 GHS/QoL (pembrolizumab vs cetuximab-chemotherapy: HR, 1.38; 95% CI, 0.95-2.00; pembrolizumab-chemotherapy vs cetuximab-chemotherapy: HR, 1.37; 95% CI, 0.94-2.00), as was TTD in EORTC QLQ-H&N35 pain and swallowing scores.”

Source: [Rischin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35381576/)

<a id="topic-2.2.1.8.1-3"></a>

###### Real-world quality of life during pembrolizumab treatment

> “We retrospectively analyzed the data of patients with recurrent or metastatic head and neck cancer who underwent pembrolizumab treatment at our institution between 2020 and 2023.”
> “In total, 68 patients were included in the analysis. The mean GHS score increased from 57.0 at baseline to 62.5 at nine weeks, indicating a trend toward improvement (p=0.051). The GHS score remained higher at 18 weeks (58.7) than at baseline, although the difference was not statistically significant.”

Source: [Hihara et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42203315/)

<a id="topic-2.2.1.8.1-4"></a>

###### Health-state utility values in head and neck cancer

> “Of a total 1048 records identified by the search, 28 studies qualified for data extraction and 346 unique HSUVs were retrieved from them.”
> “There is currently a lack of research for some disease phases including recurrent and metastatic cancer, and treatment-related complications.”

Source: [Meregaglia and Cairns (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5581467/)

<a id="topic-2.2.1.8.1-5"></a>

###### Utilities used in US cost-effectiveness models of first-line treatment

> “Utilities were derived from the KEYNOTE-048 Euro-QoL five-dimension data and using a US algorithm.”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

> “A PD health utility value of 0.749 and PFS health utility value of 0.805 were associated with HNSCC”

Source: [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12083786/)

<a id="topic-2.2.1.8.1-6"></a>

###### Time spent on care during immune checkpoint inhibitor treatment

> “Of 56 patients evaluated, median age was 63 years (33–85) and 84% were male. Median overall survival (OS) and grade 3 immune-toxicities were 7.6 months and 6.2%, respectively. Median TT was 24 days (1–109), accounting for 7.6% of OS. TT accounted for 14.9% of OS in poor responders.”

Source: [Bradbury et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218434/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Monthly cost of care in recurrent or refractory disease in US community oncology

> “This retrospective observational study was conducted by using data from the Vector Oncology Data Warehouse.”
> “Through the overall study period (mean, 20.5 months), 74% of patients were hospitalized, 19% had an emergency department visit, and 100% had an office visit.”
> “The mean monthly health care cost for the overall study period was $14,391 (95% CI, 12,739-16,044). Hospitalization costs represented ~57% of the total expenditures.”

Source: [Fisher et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29530457/)

<a id="topic-2.2.1.8.2-2"></a>

###### Resource use and costs before and after immuno-oncology agents

> “Of 716 patients identified (pre-IO = 265, post-IO = 451) 46.3% of post-IO patients received IO post-platinum.”
> “Inpatient admissions during 1 L PPT: 34.1% post-IO versus 48.0% pre-IO (p= <.01). PPPM total costs of care in 1 L PPT were significantly greater post-IO ($11,535) compared to pre-IO ($9,054, p=.002).”

Source: [Abraham et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31581922/)

<a id="topic-2.2.1.8.2-3"></a>

###### Incremental costs of metastatic and recurrent disease in Medicare and commercial claims

> “Administrative claims from Medicare- and privately-insured individuals during 2004-2008 were used in this retrospective database study of patients with advanced HNC.”
> “The 6-month incremental adjusted total costs were $60,414 per patient for mHNC and $21,141 per patient for rHNC (p<0.0001). Approximately 46-58% of the incremental cost was attributable to outpatient visits, 27-37% to inpatient costs and 11-13% to pharmacy, depending on the HNC cohort.”

Source: [Kim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22475042/)

<a id="topic-2.2.1.8.2-4"></a>

###### Costs associated with recurrence in older patients in SEER-Medicare

> “Older patients diagnosed with LA HNSCC (2007-2019) from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data were included.”
> “Recurrence was associated with higher HCRU and monthly health care costs in both resected ($3,831; 95% CI = $2,319-$5,360) and unresected ($4,730; 95% CI = $3,611-$5,870) groups (P < 0.001).”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-2.2.1.8.2-5"></a>

###### Systematic review of head and neck cancer costs

> “Data from these studies suggested that costs generally are higher for HNC patients with recurrent and/or metastatic disease, for patients undergoing surgery, and for those patients insured by private payers.”

Source: [Wissinger et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4153967/)

<a id="topic-2.2.1.8.2-6"></a>

###### Cost-effectiveness of first-line pembrolizumab from a US payer perspective

> “A three-state partitioned-survival model was used to project costs and outcomes over 20 years with 3% annual discounting.”
> “In the CPS ≥1 R/M HNSCC population, pembrolizumab monotherapy was dominant vs. EXTREME and TPEx regimens, and cost-effective (at $100,000/QALY threshold) vs. platinum+5-FU ($86,827/QALY) and cisplatin + paclitaxel ($81,473/QALY).”
> “Pembrolizumab combination therapy in the overall R/M HNSCC population was dominant vs. TPEx regimen, and cost-effective vs. EXTREME regimen ($1769/QALY), platinum+5-FU ($81,989/QALY), and cisplatin + paclitaxel ($89,505/QALY).”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

<a id="topic-2.2.1.8.2-7"></a>

###### Cost-effectiveness of first-line pembrolizumab by PD-L1 combined positive score

> “When compared with cetuximab plus chemotherapy, the pembrolizumab monotherapy strategy was dominated by lower cost and better efficacy in all three populations.”
> “The incremental costs and quality adjusted life years (QALYs) yielded by pembrolizumab plus chemotherapy compared with cetuximab plus chemotherapy were $16016.88 and 0.11 in the total population, and $24467.47 and 0.18 and $30448.46 and 0.20 in the populations with a PD-L1 CPS ≥ 1 and CPS ≥ 20, respectively, leading to ICERs of $147876.14, $134237.84, and $153660.78 per QALY, respectively.”

Source: [She et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35483156/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of HPV-negative head and neck squamous cell carcinoma on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Employment and productivity after recurrence in patients and caregivers

> “Although these results did not significantly differ based on cancer type, the highest proportions of patients noting that recurrence affected employment had gastric cancer (68.4%), HN cancer (66.7%), or TNBC (57.1%).”
> “The greatest impacts on the work productivity score were reported for those caring for people with HN cancer (mean [SD] score: 6.5 [2.1]) and TNBC (6.1 [2.5]) and on the activity score for those caring for people with HN cancer (6.1 [1.8]).”
> “From pre- to post-first recurrence, the proportion of caregivers working full-time decreased significantly from 86.1% to 3.0%”

Source: [Aguiar-Ibáñez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11792841/)

<a id="topic-2.2.1.8.3-2"></a>

###### Financial toxicity in patients and caregivers

> “At diagnosis, the median COST score was 17 (range, 2-41), and 31 (48%) reported high FT by FDQ.”
> “Mixed-effects logistic modeling showed similar odds of high FT over time for patients and caregivers (odds ratio, 1.66; 95% CI, 0.11-273.14).”

Source: [Mady et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163717/)

> “Patients reported a median COST score of 27 while caregivers reported a median COST score of 16. Approximately 25.9% of patients and 44.4% of caregivers reported high financial toxicity (COST < 17.5).”

Source: [Nguyen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10116977/)

<a id="topic-2.2.1.8.3-3"></a>

###### Out-of-pocket expenses compared with other cancers

> “Median annual medical expenses ($8384 vs $5978; difference, $2406; 95% CI, $795-$4017) and relative out-of-pocket expenses (3.93% vs 3.07%; difference, 0.86%; 95% CI, 0.06%-1.66%) were higher for patients with HNC than for patients with other cancers.”

Source: [Massa et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439752/)

<a id="topic-2.2.1.8.3-4"></a>

###### Out-of-pocket costs during survivorship in commercial claims

> “Throughout the survivorship period, median total and OOP costs were $372 per month and $31 per month higher than baseline costs, respectively, with variation in expenses by demographic information, health plan type, and oncologic variables.”

Source: [Massa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9585466/)

<a id="topic-2.2.1.8.3-5"></a>

###### Psychological burden of caregivers

> “Fifty studies (15 cohort studies, 35 cross-sectional studies), including 4289 informal caregivers, were included in the review.”
> “Findings from these studies indicated a high prevalence of clinically significant distress among HNC caregivers: anxiety symptoms meeting clinical thresholds affected 29% to 63% of participants, while clinically significant depression was reported in 10% to 39% of cases.”

Source: [Xie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13447393/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### PD-L1 testing requirement in the pembrolizumab label

> “KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test”
> “Information on FDA-authorized tests for patient selection is available at:”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.1.8.4-2"></a>

###### PD-L1 testing patterns before first-line therapy in US practice

> “Adults with R/M HNSCC initiating 1L systemic therapy were included from a U.S. nationwide database primarily compromised of community practices (07/01/2019-12/31/2023).”
> “Of 2,207 patients, 32.7 % received PD-L1 testing before 1L therapy initiation, 17.4 % after 1L therapy initiation, and 50.0 % were never tested.”
> “This study revealed low utilization of PD-L1 testing to guide treatment choice and impactful gaps between specimen collection, the receipt of results, and 1L therapy initiation.”

Source: [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/)

<a id="topic-2.2.1.8.4-3"></a>

###### HPV testing rates in oropharyngeal squamous cell carcinoma

> “Among the 146,176 patients with OPSCC and known HPV testing included in the study, the overall HPV testing rate was 88.4% (N = 129,240/146,176). Testing for HPV mediation significantly increased during the study period from 56.0% to 93.6% (adjusted odds ratio [OR]: 1.23, 95% CI: 1.22-1.24, P < .001).”

Source: [Costantino et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40211672/)

> “Human papilloma virus testing was most frequent among the oropharynx group (22% tested, 52% positive).”

Source: [Fisher et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29530457/)

<a id="topic-2.2.1.8.4-4"></a>

###### HPV testing methods recommended by the College of American Pathologists

> “For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC.”
> “Pathologists should not routinely perform HR-HPV testing on patients with primary oral cavity, laryngeal, nasopharyngeal, or hypopharyngeal SCCs of the head and neck for prognostic purposes.”

Source: [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

Additional sources: [Lewis et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40126379/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 PD-1 Inhibitor Monotherapy

<a id="topic-2.2.2.1.1-1"></a>

###### FDA-approved first-line indication: pembrolizumab as a single agent

> “KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.1-2"></a>

###### KEYNOTE-048 design, stratification, and population

> “The efficacy of KEYTRUDA was investigated in KEYNOTE-048 (NCT02358031), a randomized, multicenter, open-label, active-controlled trial conducted in 882 patients with metastatic HNSCC who had not previously received systemic therapy for metastatic disease or with recurrent disease who were considered incurable by local therapies.”
> “Randomization was stratified by tumor PD-L1 expression (TPS ≥50% or <50%) according to the PD-L1 IHC 22C3 pharmDx assay, HPV status according to p16 IHC (positive or negative), and ECOG PS (0 vs. 1).”
> “A retrospective re-classification of patients’ tumor PD-L1 status according to CPS using the PD-L1 IHC 22C3 pharmDx assay was conducted using the tumor specimens used for randomization.”
> “The main efficacy outcome measures were OS and PFS as assessed by BICR according to RECIST v1.1 (modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ) sequentially tested in the subgroup of patients with CPS ≥20, the subgroup of patients with CPS ≥1, and the overall population.”
> “Twenty-two percent of patients’ tumors were HPV-positive, 23% had PD-L1 TPS ≥50%, and 95% had Stage IV disease (Stage IVA 19%, Stage IVB 6%, and Stage IVC 70%).”
> “Eighty-five percent of patients’ tumors had PD-L1 expression of CPS ≥1 and 43% had CPS ≥20.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.1-3"></a>

###### KEYNOTE-048 efficacy of pembrolizumab monotherapy at the interim analysis: CPS ≥1 and CPS ≥20 subgroups

| Endpoint | CPS ≥1 | CPS ≥20 |
| --- | --- | --- |
| Participants, pembrolizumab 200 mg every 3 weeks | “n=257” | “n=133” |
| Participants, cetuximab with platinum and FU | “n=255” | “n=122” |
| Median OS, pembrolizumab, months (95% CI) | “12.3 (10.8, 14.9)” | “14.9 (11.6, 21.5)” |
| Median OS, cetuximab with platinum and FU, months (95% CI) | “10.3 (9.0, 11.5)” | “10.7 (8.8, 12.8)” |
| OS hazard ratio (95% CI) | “0.78 (0.64, 0.96)” | “0.61 (0.45, 0.83)” |
| Median PFS, pembrolizumab, months (95% CI) | “3.2 (2.2, 3.4)” | “3.4 (3.2, 3.8)” |
| Median PFS, cetuximab with platinum and FU, months (95% CI) | “5.0 (4.8, 5.8)” | “5.0 (4.8, 6.2)” |
| PFS hazard ratio (95% CI) | “1.15 (0.95, 1.38)” | “0.97 (0.74, 1.27)” |
| ORR, pembrolizumab (95% CI) | “19% (14.5, 24.4)” | “23% (16.4, 31.4)” |
| ORR, cetuximab with platinum and FU (95% CI) | “35% (29.1, 41.1)” | “36% (27.6, 45.3)” |
| Median duration of response, pembrolizumab, months (range) | “20.9 (1.5+, 34.8+)” | “20.9 (2.7, 34.8+)” |
| Median duration of response, cetuximab with platinum and FU, months (range) | “4.5 (1.2+, 28.6+)” | “4.2 (1.2+, 22.3+)” |

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.1-4"></a>

###### KEYNOTE-048 pembrolizumab monotherapy: final analysis and the CPS 1-19 subgroup

> “At the time of the interim and final analyses, there was no significant difference in OS between the KEYTRUDA single agent arm and the control arm for the overall population.”
> “At the pre-specified final OS analysis comparing KEYTRUDA as a single agent to cetuximab in combination with chemotherapy, the hazard ratio for the subgroup of patients with CPS ≥1 was 0.74 (95% CI: 0.61, 0.90) and the hazard ratio for the subgroup of patients with CPS ≥20 was 0.58 (95% CI: 0.44, 0.78).”
> “In an exploratory subgroup analysis for patients with CPS 1-19 HNSCC at the time of the pre-specified final OS analysis, the median OS was 10.8 months (95% CI: 9.0, 12.6) for KEYTRUDA as a single agent and 10.1 months (95% CI: 8.7, 12.1) for cetuximab in combination with chemotherapy, with an HR of 0.86 (95% CI: 0.66, 1.12).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.1-5"></a>

###### KEYNOTE-048 primary publication: pembrolizumab monotherapy overall survival

> “Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more.”
> “At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]).”
> “Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis.”
> “grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group”
> “pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.”

Source: [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/)

<a id="topic-2.2.2.1.1-6"></a>

###### KEYNOTE-048 four-year follow-up: pembrolizumab monotherapy

> “The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).”
> “Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations (Data Supplement).”
> “The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population”
> “A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone.”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.1-7"></a>

###### KEYNOTE-048 five-year follow-up: pembrolizumab monotherapy

> “Median OS remained longer for pembrolizumab versus EXTREME in the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20 (HR, 0.61; 95 % CI, 0.46-0.81) and CPS ≥ 1 populations (HR, 0.74; 95 % CI, 0.61-0.89), and similar in the total population (HR, 0.82; 95 % CI, 0.69-0.97).”
> “The 5-year OS rate in the total population was 14.4 % for pembrolizumab versus 6.5 % for EXTREME”

Source: [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/)

<a id="topic-2.2.2.1.1-8"></a>

###### Pembrolizumab monotherapy by PD-L1 CPS subgroup: CPS 1-19 and CPS <1

> “For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 subgroup (hazard ratio [HR], 1.51 [95% CI, 0.96 to 2.37]) and 10.8 versus 10.1 months in the CPS 1-19 subgroup (HR, 0.86 [95% CI, 0.66 to 1.12]).”
> “In the PD-L1 CPS < 1 subgroup, the ORR was 4.5% (n = 2; 95% CI, 0.6 to 15.5) for pembrolizumab versus 42.2% (n = 19; 95% CI, 27.7 to 57.8) for cetuximab-chemotherapy (Table 2 ).”
> “In the PD-L1 CPS 1-19 subgroup, the ORR was 14.5% (n = 18; 95% CI, 8.8 to 22.0) for pembrolizumab versus 33.8% (n = 45; 95% CI, 25.9 to 42.5) for cetuximab-chemotherapy (Table 2 ).”
> “Efficacy outcomes for the PD-L1 CPS < 1 and CPS 1-19 subgroups (OS, PFS, and ORR) were not prespecified.”

Source: [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

<a id="topic-2.2.2.1.1-9"></a>

###### Guideline recommendation: ASCO

> “Recommendation 2.1. Pembrolizumab monotherapy or pembrolizumab, platinum, and fluorouracil (5-FU) should be offered as first-line treatment for patients with recurrent or metastatic HNSCC with a CPS ≥ 1 (Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).”
> “Recommendation 1.2. PD-L1 CPS ≥ 1 should be interpreted as positive and correlates with a clinical benefit to PD-1 inhibitors (Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).”
> “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression,”
> “However, current data do not support changing recommendations for the addition or exclusion of anti–PD-1 therapies in the recurrent and/or metastatic setting with regard to the HPV status.”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.1-10"></a>

###### Guideline recommendation: NCCN

> “The panel also considers pembrolizumab monotherapy as a preferred first-line option for patients with CPS ≥1 (category 1 if CPS ≥20).”

Source: [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 PD-1 Inhibitor Plus Platinum and Fluorouracil

<a id="topic-2.2.2.1.2-1"></a>

###### FDA-approved first-line indication: pembrolizumab with platinum and fluorouracil

> “KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.2-2"></a>

###### KEYNOTE-048 regimen: pembrolizumab with platinum and fluorouracil

> “KEYTRUDA 200 mg intravenously every 3 weeks, carboplatin AUC 5 mg/mL/min intravenously every 3 weeks or cisplatin 100 mg/m2 intravenously every 3 weeks, and FU 1000 mg/m2/day as a continuous intravenous infusion over 96 hours every 3 weeks (maximum of 6 cycles of platinum and FU)”
> “Treatment with KEYTRUDA continued until RECIST v1.1-defined progression of disease as determined by the investigator, unacceptable toxicity, or a maximum of 24 months.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.2-3"></a>

###### KEYNOTE-048 efficacy of pembrolizumab with platinum and fluorouracil at the interim analysis: overall population

| Endpoint | Pembrolizumab with platinum and FU | Cetuximab with platinum and FU |
| --- | --- | --- |
| Participants | “n=281” | “n=278” |
| Median OS, months (95% CI) | “13.0 (10.9, 14.7)” | “10.7 (9.3, 11.7)” |
| OS hazard ratio (95% CI) | “0.77 (0.63, 0.93)” | Reference |
| Median PFS, months (95% CI) | “4.9 (4.7, 6.0)” | “5.1 (4.9, 6.0)” |
| PFS hazard ratio (95% CI) | “0.92 (0.77, 1.10)” | Reference |
| ORR (95% CI) | “36% (30.0, 41.5)” | “36% (30.7, 42.3)” |
| Median duration of response, months (range) | “6.7 (1.6+, 30.4+)” | “4.3 (1.2+, 27.9+)” |

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.2-4"></a>

###### KEYNOTE-048 pembrolizumab with platinum and fluorouracil: final analysis by CPS subgroup

> “At the pre-specified final OS analysis for the ITT population, the hazard ratio was 0.72 (95% CI: 0.60, 0.87).”
> “In addition, KEYNOTE-048 demonstrated a statistically significant improvement in OS for the subgroups of patients with PD-L1 CPS ≥1 (HR=0.65, 95% CI: 0.53, 0.80) and CPS ≥20 (HR=0.60, 95% CI: 0.45, 0.82).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.2-5"></a>

###### KEYNOTE-048 primary publication: pembrolizumab with chemotherapy overall survival

> “Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63-0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45-0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53-0·80], p<0·0001) at final analysis.”
> “235 (85%) of 276 in the pembrolizumab with chemotherapy group”
> “Based on the observed efficacy and safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC”

Source: [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/)

<a id="topic-2.2.2.1.2-6"></a>

###### KEYNOTE-048 four-year follow-up: pembrolizumab with chemotherapy

> “The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population (HR, 0.71; 95% CI, 0.59 to 0.85; nominal one-sided P = .00008; Figs 2D-2F).”
> “The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population”
> “Any-grade treatment-related AEs occurred in 58.3% (n = 175) of patients in the pembrolizumab-alone group, 95.7% (n = 264) in the pembrolizumab-chemotherapy group, and 96.9% (n = 278) in the cetuximab-chemotherapy group (Data Supplement).”
> “Grade ≥ 3 treatment-related AEs were reported in 17.0% (n = 51), 71.7% (n = 198), and 69.3% (n = 199) of patients, respectively”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.2-7"></a>

###### KEYNOTE-048 five-year follow-up: pembrolizumab with chemotherapy

> “Pembrolizumab-chemotherapy prolonged median OS in the PD-L1 CPS ≥ 20 (HR, 0.63; 95 % CI, 0.47-0.84), CPS ≥ 1 (HR, 0.65; 95 % CI, 0.53-0.79), and total (HR, 0.72; 95 % CI, 0.60-0.86) populations.”
> “16.0 % for pembrolizumab-chemotherapy versus 5.2 % for EXTREME”
> “These 5-year follow-up results support the use of pembrolizumab and pembrolizumab-chemotherapy as first-line standards of care for R/M HNSCC.”

Source: [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/)

<a id="topic-2.2.2.1.2-8"></a>

###### Pembrolizumab with chemotherapy by PD-L1 CPS subgroup: CPS 1-19 and CPS <1

> “For pembrolizumab-chemotherapy versus cetuximab-chemotherapy, the median overall survival was 11.3 versus 10.7 months in the PD-L1 CPS < 1 subgroup (HR, 1.21 [95% CI, 0.76 to 1.94]) and 12.7 versus 9.9 months in the CPS 1-19 subgroup (HR, 0.71 [95% CI, 0.54 to 0.94]).”
> “In the PD-L1 CPS 1-19 subgroup, the ORR was 29.3% (n = 34; 95% CI, 21.2 to 38.5) for pembrolizumab-chemotherapy versus 33.6% (n = 42; 95% CI, 25.4 to 42.6) for cetuximab-chemotherapy (Table 2 ).”
> “Increased efficacy of pembrolizumab or pembrolizumab-chemotherapy was observed with increasing PD-L1 expression.”

Source: [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

<a id="topic-2.2.2.1.2-9"></a>

###### Guideline recommendation: ASCO

> “Recommendation 2.2. Pembrolizumab, platinum, and 5-FU may be offered as first-line treatment for patients with recurrent or metastatic HNSCC with a CPS < 1 (Type: Evidence based, benefits outweigh harms; Evidence quality: Moderate; Strength of recommendation: Strong).”
> “Deciding on the plausibility of chemoimmunotherapy versus immunotherapy in patients with previously untreated recurrent or metastatic HNSCC must take into consideration the clinical presentation and urgency for achieving a response.”
> “Chemoimmunotherapy may therefore be a plausible option even in biomarker-positive disease in case a rapid reduction in tumor burden is deemed clinically necessary.”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.2-10"></a>

###### Guideline recommendation: NCCN

> “the panel considers pembrolizumab/platinum/5-FU a preferred first-line option (category 1) for all patients with recurrent, unresectable, or metastatic disease who have no surgical or radiotherapeutic option.”

Source: [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 EGFR Monoclonal Antibody Plus Platinum-based Chemotherapy

<a id="topic-2.2.2.1.3-1"></a>

###### FDA-approved first-line indication: cetuximab with platinum-based therapy and fluorouracil

> “in combination with platinum-based therapy with fluorouracil for the first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN.”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.2.2.1.3-2"></a>

###### EXTREME design and regimen

> “EXTREME (NCT00122460) was an open-label, randomized, multicenter, controlled trial of 442 patients with recurrent locoregional disease or metastatic SCCHN.”
> “Cisplatin (100 mg/m2 intravenously on Day 1) or carboplatin (AUC 5 mg/mL*min intravenously on Day 1) and fluorouracil (1000 mg/m2/day intravenously on Days 1–4) were administered every 3 weeks (1 cycle) for a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity.”
> “Cetuximab was administered intravenously at a 400 mg/m2 initial dose, followed by a 250 mg/m2 weekly dose.”
> “In the absence of disease progression or unacceptable toxicity after completion of 6 planned courses of platinum-based therapy, weekly cetuximab as a single-agent could be continued until disease progression or unacceptable toxicity.”
> “Thirty-four percent of patients had oropharyngeal, 25% laryngeal, 20% oral cavity, and 14% hypopharyngeal primary tumors.”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.2.2.1.3-3"></a>

###### EXTREME efficacy in the label

| Endpoint | Cetuximab with platinum-based therapy and fluorouracil | Platinum-based therapy and fluorouracil |
| --- | --- | --- |
| Participants | “(n=222)” | “(n=220)” |
| Median OS, months | “10.1” | “7.4” |
| OS hazard ratio (95% CI) | “0.80 (0.64, 0.98)” | Reference |
| Median PFS, months | “5.5” | “3.3” |
| PFS hazard ratio (95% CI) | “0.57 (0.46, 0.72)” | Reference |
| ORR | “35.6%” | “19.5%” |

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### EXTREME primary publication

> “Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracil) significantly prolonged the median overall survival from 7.4 months in the chemotherapy-alone group to 10.1 months in the group that received chemotherapy plus cetuximab (hazard ratio for death, 0.80; 95% confidence interval, 0.64 to 0.99; P=0.04).”
> “The addition of cetuximab prolonged the median progression-free survival time from 3.3 to 5.6 months (hazard ratio for progression, 0.54; P<0.001) and increased the response rate from 20% to 36% (P<0.001).”
> “Sepsis occurred in 9 patients in the cetuximab group and in 1 patient in the chemotherapy-alone group (P=0.02).”
> “Of 219 patients receiving cetuximab, 9% had grade 3 skin reactions and 3% had grade 3 or 4 infusion-related reactions.”

Source: [Vermorken et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18784101/)

<a id="topic-2.2.2.1.3-5"></a>

###### EXTREME safety in the label

> “In EXTREME, fatal cardiac disorders and/or sudden death occurred in 3% of 219 patients treated with a cetuximab product in combination with platinum-based therapy and fluorouracil.”
> “Because ERBITUX provides approximately 22% higher exposure relative to the cetuximab product, the data provided below may underestimate the incidence and severity of adverse reactions anticipated with ERBITUX for this indication”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

###### Docetaxel, cisplatin, and cetuximab versus EXTREME: TPExtreme

> “The TPEx regimen consisted of docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently).”
> “Overall survival did not differ significantly between the groups (median 14·5 months [95% CI 12·5-15·7] in the TPEx group and 13·4 months [12·2-15·4] in the EXTREME group; hazard ratio 0·89 [95% CI 0·74-1·08]; p=0·23).”
> “214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p<0·0001).”
> “The TPEx regimen could provide an alternative to standard of care with the EXTREME regimen in the first-line treatment of patients with recurrent or metastatic HNSCC, especially for those who might not be good candidates for up-front pembrolizumab treatment.”

Source: [Guigay et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33684370/)

<a id="topic-2.2.2.1.3-7"></a>

###### Cetuximab with chemotherapy as the KEYNOTE-048 comparator

> “239 (83%) of 287 in the cetuximab with chemotherapy group”
> “Adverse events led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (12%) in the pembrolizumab with chemotherapy group, and 28 (10%) in the cetuximab with chemotherapy group.”

Source: [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/)

<a id="topic-2.2.2.1.3-8"></a>

###### Guideline position of cetuximab with chemotherapy: ASCO

> “Although a small number of patients were in the PD-L1 CPS < 1 subgroup (39 and 43 respectively) and the study was not powered to evaluate efficacy of pembrolizumab with chemotherapy in this subgroup, cetuximab with chemotherapy may also be considered for these patients.”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.3-9"></a>

###### Guideline position of cetuximab with chemotherapy: NCCN

> “Other combination regimens recommended by the panel for treatment of metastatic HNSCC include (1) cisplatin or carboplatin, plus 5-FU with cetuximab (category 1; preferred)”
> “or (5) cetuximab with a platinum and a taxane”

Source: [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Cytotoxic Chemotherapy

<a id="topic-2.2.2.1.4-1"></a>

###### Platinum-based chemotherapy as first-line treatment

> “Platinum-based chemotherapy is often used as first-line treatment for patients with metastatic or recurrent squamous cell carcinoma (SCC) of the head and neck.”

Source: [National Cancer Institute Oropharyngeal Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/oropharyngeal-treatment-pdq)

<a id="topic-2.2.2.1.4-2"></a>

###### Chemotherapy responses without demonstrated survival benefit

> “Although chemotherapy has been shown to induce responses, no increase in survival has been demonstrated.”

Source: [National Cancer Institute Lip and Oral Cavity Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/lip-mouth-treatment-pdq)

<a id="topic-2.2.2.1.4-3"></a>

###### Platinum plus fluorouracil versus methotrexate: randomized phase 3 trial

> “Two hundred seventy-seven patients diagnosed with SCC of the head and neck were randomized to one of three treatments”
> “The complete and partial response rates were 32% for cisplatin plus 5-FU, 21% for carboplatin plus 5-FU, and 10% for MTX.”
> “Median response durations and median survival times were similar for all three treatment groups.”
> “We conclude that combination chemotherapy resulted in improved response rates but was associated with an increased toxicity and no improvement in overall survival.”

Source: [Forastiere et al. (1992)](https://pubmed.ncbi.nlm.nih.gov/1634913/)

<a id="topic-2.2.2.1.4-4"></a>

###### Cisplatin plus paclitaxel versus cisplatin plus fluorouracil: randomized phase 3 trial

> “Two hundred eighteen patients with locally advanced, recurrent, or metastatic disease were randomly assigned to CF (cisplatin 100 mg/m2 day 1 and fluorouracil 1,000 mg/m2/24 hours by continuous intravenous infusion day 1 through 4) or CP (cisplatin 75 mg/m2 day 1 and paclitaxel 175 mg/m2 over 3 hours on day 1).”
> “Estimated median survival was 8.7 months in the CF group and 8.1 month in the CP group. Objective response rate (complete response plus partial response) was 27% in the CF group and 26% in the CP group.”
> “A total of 12 deaths occurred (CF, seven; CP, five) during treatment”

Source: [Gibson et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15908667/)

<a id="topic-2.2.2.1.4-5"></a>

###### Taxane in place of fluorouracil with pembrolizumab: single-arm phase 4 trial

> “Patients received pembrolizumab 200 mg intravenously once every 3 weeks for ≤35 cycles and carboplatin AUC 5 mg/mL/min intravenously once every 3 weeks for ≤6 cycles and investigator's choice of paclitaxel 100 mg/m2 on days 1 and 8 or 175 mg/m2 on day 1, intravenously once every 3 weeks.”
> “At this final analysis, 49 (49%) of 101 patients had an objective response (95% CI, 38.4 to 58.7), including seven patients (7%) with a confirmed complete response.”
> “Of the 101 treated patients, grade 3-5 and serious treatment-related adverse events occurred in 76 (75%) and 27 (27%), respectively.”

Source: [Dzienis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11361359/)

<a id="topic-2.2.2.1.4-6"></a>

###### Pembrolizumab plus platinum plus taxane: United States real-world outcomes

> “the toxicity of 5-FU has motivated the study of alternate combinations that replace 5-FU with a taxane.”
> “The study population comprised 83 individuals (80.7% male) with a median age of 64 years.”
> “The median (95% CI) rwOS was 14.9 (8.8-23.3) months, rwToT was 5.3 (4.0-8.2) months”

Source: [Black et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10881782/)

<a id="topic-2.2.2.1.4-7"></a>

###### Single-agent methotrexate, docetaxel, or cetuximab as the comparator after platinum

> “Two phase III trials, KEYNOTE-040 and CheckMate 141, evaluated anti–PD-1 therapies, pembrolizumab (KEYNOTE-040) and nivolumab (CheckMate 141), compared to standard-of-care single-agent therapy (methotrexate, docetaxel, or cetuximab).”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.4-8"></a>

###### Single-agent standard therapy after platinum: response and survival in a phase 3 control arm

> “The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group.”
> “Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group.”

Source: [Ferris et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5564292/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Therapies After Progression on PD-1 Inhibitor and Platinum

<a id="topic-2.2.2.1.5-1"></a>

###### Amivantamab and hyaluronidase-lpuj: indication and limitation of use

> “RYBREVANT FASPRO is indicated as a single agent for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody.”
> “Limitations of use: RYBREVANT FASPRO is not indicated as a treatment for patients with oropharyngeal squamous cell carcinoma (OPSCC) that is human papillomavirus (HPV)-associated (i.e., by p16 IHC).”
> “This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).”

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### Amivantamab and hyaluronidase-lpuj: date of accelerated approval

> “On November 5, 2026, the Food and Drug Administration granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody.”
> “This application was granted priority review. Amivantamab and hyaluronidase-lpuj received breakthrough therapy designation.”

Source: [FDA (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and)

<a id="topic-2.2.2.1.5-3"></a>

###### OrigAMI-4: population and prior therapy

> “The efficacy of RYBREVANT FASPRO as a single agent was evaluated in OrigAMI-4 (NCT06385080), a multicenter, open-label, multi-cohort clinical trial. The primary efficacy population included 102 patients with recurrent or metastatic HNSCC.”
> “Patients with HPV-associated OPSCC based on p16 testing results (only required for OPSCC), were excluded from the primary efficacy population.”
> “Eligible patients must have received previous treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody (in combination or as separate lines of therapy).”
> “52% had one prior line and 48% had two prior lines of systemic therapies.”

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

###### OrigAMI-4: efficacy results

| Outcome | RYBREVANT FASPRO (N=102) |
| --- | --- |
| Overall response rate (95% CI) | “42% (32%, 52%)” |
| Complete response | “15%” |
| Partial response | “28%” |
| Duration of response, range (months) | “1.4+, 19.7+” |
| Patients with duration of response of 6 months or longer | “56%” |

Source: [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

###### First approval in 10 years after prior platinum-based chemotherapy

> “This is the first approval in 10 years of a drug for patients with recurrent or metastatic HNSCC who had received prior platinum-based chemotherapy.”
> “Currently approved therapies are associated with an overall response rate of around 20% or less and poor outcomes.”

Source: [FDA press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma)

<a id="topic-2.2.2.1.5-6"></a>

###### Cetuximab monotherapy after platinum: indication and response

> “as a single-agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed.”
> “EMR 62202-016 was a single-arm, multicenter clinical trial in 103 patients with recurrent or metastatic SCCHN. All patients had documented disease progression within 30 days of a platinum-based chemotherapy regimen.”
> “The ORR was 13% (95% CI 7%, 21%). Median duration of response (DoR) was 5.8 months (range 1.2 to 5.8 months).”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

###### PD-1 inhibitors after platinum in disease not previously treated with a PD-1 inhibitor

> “Pembrolizumab or nivolumab should be offered to patients with platinum-refractory recurrent or metastatic HNSCC, regardless of CPS status (Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).”
> “The combination of anti–PD-1 inhibitors with other systemic treatments has been investigated in platinum-refractory disease; however, no combination has become standard of care to date.”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.5-8"></a>

###### Pembrolizumab versus methotrexate, docetaxel, or cetuximab after platinum: overall survival

> “survival in the intention-to-treat population was 8·4 months (95% CI 6·4-9·4) with pembrolizumab and 6·9 months (5·9-8·0) with standard of care (hazard ratio 0·80, 0·65-0·98; nominal p=0·0161).”

Source: [Cohen et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30509740/)

<a id="topic-2.2.2.1.5-9"></a>

###### Next-line therapy after first-line pembrolizumab in KEYNOTE-048

> “The objective response rate on second-course pembrolizumab was 27.3% (3 of 11).”
> “PFS2 was similar after pembrolizumab and longer after pembrolizumab-chemotherapy on next-line taxanes and shorter after pembrolizumab and similar after pembrolizumab-chemotherapy on next-line nontaxanes.”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.5-10"></a>

###### Salvage chemotherapy after anti-PD-(L)1 therapy: retrospective cohort

> “Retrospective cohort analysis of 63 R/M patients treated with SCT after antiPD-(L1)-based therapy between January 2015 and August 2022.”
> “Up to 71% received SCT as third line or beyond. ORR to SCT was 49% with higher rates in PD-L1 positive tumors, 71% vs. 18% (p=0.001), and cetuximab-containing regimens, 68% vs. 39% (p=0.026).”
> “OS and PFS were 9.3 months (95% CI, 6.5–12.3) and 4.1 months (95% CI, 3.0–5.8) respectively.”

Source: [Llop et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625818/)

<a id="topic-2.2.2.1.5-11"></a>

###### Cetuximab-based salvage chemotherapy after immune checkpoint inhibitors: real-world cohort

> “In recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) there is no established standard therapy after progression to immune checkpoint inhibitors (ICI).”
> “Among 80 patients, 96% and 100% received cetuximab-based first and second SCAI, respectively”
> “First SCAI: ORR of 59% (41/70; 31 partial and 10 complete responses)”
> “DoR of 9.4 months, and PFS and OS of 5.9 and 12.4 months, respectively”
> “grade 3–5 AEs, 38.7% (first SCAI) and 47% (second SCAI) with no toxic deaths.”

Source: [Cabezas-Camarero et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12827138/)

<a id="topic-2.2.2.1.5-12"></a>

###### Range of response and survival with conventional salvage regimens

> “Conventional salvage regimens (taxanes, methotrexate, cetuximab) yield response rates of 21–69% but with short median PFS (2.9–5.5 months) and OS (6.3–13.3 months)”
> “As a result, there is no clear standard of care choice in second-line treatment”

Source: [Abraham et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12691436/)

Additional sources: [Reverdy et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37562096/); [Wakasaki et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31128940/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Salvage Surgery and Reirradiation for Locoregional Recurrence

<a id="topic-2.2.2.1.6-1"></a>

###### Recurrent oral cavity cancer: surgery and radiation therapy by initial treatment

> “Surgery is the preferred treatment if radiation therapy was used initially.”
> “radiation therapy, or a combination of these treatments may be considered if surgery was used to treat the lesion initially.”
> “both surgical salvage after primary radiation therapy and radiation therapy after primary surgery give poor results.”

Source: [National Cancer Institute Lip and Oral Cavity Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/lip-mouth-treatment-pdq)

<a id="topic-2.2.2.1.6-2"></a>

###### Recurrent laryngeal cancer: salvage surgery and reirradiation

> “Salvage is possible for failures of surgery alone or of radiation therapy alone”
> “Selected patients may be candidates for partial laryngectomy after high-dose radiation therapy has failed.”
> “Re-irradiation for laryngeal salvage following radiation therapy failure has resulted in long-term survival in a small number of patients; it may be considered for small recurrences after radiation therapy, especially in patients who refuse or are not candidates for laryngectomy.”
> “Salvage after previous combined total laryngectomy and radiation therapy is poor.”

Source: [National Cancer Institute Laryngeal Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/laryngeal-treatment-pdq)

<a id="topic-2.2.2.1.6-3"></a>

###### Recurrent oropharyngeal cancer: surgical resection and additional radiation therapy

> “The management of metastatic and recurrent carcinomas of the oropharynx is complex and requires multidisciplinary input to establish the optimal treatment.”
> “Surgical resection, if technically feasible and the tumor does not respond to radiation therapy.”
> “Radiation therapy, if the tumor is not completely removed by surgery and curative doses of radiation have not been given previously.”
> “Additional radiation therapy using conventionally fractionated radiation therapy, or hyperfractionated radiation therapy (HFX) with concurrent chemotherapy.”

Source: [National Cancer Institute Oropharyngeal Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/oropharyngeal-treatment-pdq)

<a id="topic-2.2.2.1.6-4"></a>

###### International consensus on reirradiation

> “Reirradiation can be considered for some patients with recurrent or second primary head and neck squamous cell carcinoma arising within previously irradiated regions, a clinical scenario associated with few therapeutic options.”
> “However, evidence remains heterogeneous, and clinical choices are challenged by substantial variability in patient presentation, previous treatments, and toxicity risk.”

Source: [Biau et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42372755/)

<a id="topic-2.2.2.1.6-5"></a>

###### Radiation therapy combined with immunotherapy for locoregional recurrence or oligometastatic disease

> “For patients with oligometastatic HNSCC, radiation therapy is safe to give concurrently with immunotherapy for the purpose of palliation or local control, but should not be given to enhance response to immunotherapy outside of a clinical trial (Type: Evidence based, no net benefit; Evidence quality: Moderate; Strength of recommendation: Weak).”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.6-6"></a>

###### Salvage surgery versus nonsurgical management: meta-analysis

> “Fifteen studies reported survival for salvage surgery and nonsurgical management of recurrence. Five-year OS ranged from 26% to 67% for the salvage surgery groups, compared to 0% to 32% for the nonsurgical management groups. Six studies reported HRs comparing salvage surgery to nonsurgical management; the pooled HR was 0.25 (95% CI [0.16, 0.38]; p < 0.0001).”

Source: [Bulbul et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34729845/)

<a id="topic-2.2.2.1.6-7"></a>

###### Salvage surgery and survival after progression of oropharyngeal cancer

> “p16-positive tumor status (HR, 0.48; 95% CI, 0.31 to 0.74) and receipt of salvage surgery (HR, 0.48; 95% CI; 0.27 to 0.84) reduced risk of death after disease progression”

Source: [Fakhry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4195851/)

<a id="topic-2.2.2.1.6-8"></a>

###### Reirradiation with intensity-modulated radiotherapy: meta-analysis

> “A total of 17 studies involving 1635 patients were included. Fourteen (82%) of those were retrospective, and 15 (88%) were from single institution. Reirradiation with IMRT produced pooled 2-year LC and OS rates of 52% (95% confidence interval [CI], 46%-57%) and 46% (95% CI, 41%-50%), respectively.”
> “The pooled rates of late grade ≥ 3 and grade 5 toxicities were 26% (95% CI, 20%-32%) and 3.1% (95% CI, 2%-5%), respectively.”

Source: [Lee et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32437021/)

<a id="topic-2.2.2.1.6-9"></a>

###### Postoperative reirradiation with chemotherapy after salvage surgery: randomized trial

> “Between 1999 and 2005, 130 patients with head and neck cancer were treated with salvage surgery and randomly assigned to full-dose reirradiation combined with chemotherapy (RT arm) or to observation”
> “At 2 years, 39% of patients in the RT arm and 10% in the WS arm experienced grade 3 or 4 late toxicity according to Radiation Therapy Oncology Group criteria (P = .06).”
> “Full-dose reirradiation combined with chemotherapy after salvage surgery significantly improved DFS, but had no significant impact on OS.”

Source: [Janot et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18936479/)

<a id="topic-2.2.2.1.6-10"></a>

###### Palliative reirradiation with chemotherapy versus methotrexate: randomized trial

> “Due to a very slow accrual, the trial was closed after inclusion of 57 patients.”
> “re-irradiation did not improve OS compared with methotrexate (23% versus 22% at 1year, NS).”

Source: [Tortochaux et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21741720/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary: response, survival, and PD-L1 selection with first-line pembrolizumab regimens

Pembrolizumab monotherapy is approved for first-line recurrent or metastatic HNSCC with PD-L1 CPS ≥1, and pembrolizumab with platinum and fluorouracil for all first-line patients. ASCO states that “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression”. At the KEYNOTE-048 4-year follow-up, the objective response rate with pembrolizumab alone was 19.1% versus 34.9% with cetuximab-chemotherapy in the CPS ≥1 population and 16.9% versus 36.0% in the total population; with pembrolizumab-chemotherapy it was 37.2% (CPS ≥1) and 36.3% (total). Neither pembrolizumab regimen improved progression-free survival at the second interim analysis, when median progression-free survival in the CPS ≥1 subgroup was 3.2 months with pembrolizumab versus 5.0 months with cetuximab-chemotherapy. At the 4-year follow-up, median overall survival was 12.3 months with pembrolizumab (CPS ≥1) and 13.0 months with pembrolizumab-chemotherapy (total population); 5-year overall survival in the total population was 14.4% and 16.0%, and the survival curve with pembrolizumab alone reached a plateau at approximately 20%. The median duration of pembrolizumab exposure was 3.5 months with monotherapy and 5.8 months in the combination arm. In exploratory analyses that were not prespecified, median overall survival with pembrolizumab alone versus cetuximab-chemotherapy was 10.8 versus 10.1 months in the CPS 1-19 subgroup (hazard ratio 0.86, 95% CI 0.66 to 1.12), and median overall survival was 7.9 versus 11.3 months in the CPS <1 subgroup (hazard ratio 1.51, 95% CI 0.96 to 2.37).

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328); [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/); [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/); [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/); [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

<a id="topic-2.2.2.1.7-2"></a>

###### Summary: toxicity and administration of chemotherapy-containing regimens

At the KEYNOTE-048 4-year follow-up, grade ≥3 treatment-related adverse events occurred in 17.0% of participants receiving pembrolizumab alone, 71.7% receiving pembrolizumab-chemotherapy, and 69.3% receiving cetuximab-chemotherapy. Fluorouracil requires a “continuous 4-day infusion” and is associated with “cardiovascular and gastrointestinal toxicities”. In EXTREME, fatal cardiac disorders or sudden death occurred in 3% of 219 participants treated with cetuximab plus platinum and fluorouracil. With a taxane in place of fluorouracil alongside pembrolizumab and carboplatin, grade 3 to 5 treatment-related adverse events occurred in 76 of 101 treated participants (75%). NCI states that chemotherapy has been shown to induce responses with no demonstrated increase in survival; in randomized trials, cisplatin plus fluorouracil did not improve overall survival over methotrexate, and response rates were 32% with cisplatin plus fluorouracil and 10% with methotrexate in one trial, and 27% with cisplatin plus fluorouracil and 26% with cisplatin plus paclitaxel in another.

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/); [Dzienis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11361359/); [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf); [National Cancer Institute Lip and Oral Cavity Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/lip-mouth-treatment-pdq); [Forastiere et al. (1992)](https://pubmed.ncbi.nlm.nih.gov/1634913/); [Gibson et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15908667/)

<a id="topic-2.2.2.1.7-3"></a>

###### Summary: outcomes in HPV-negative disease

Response and survival with current therapy are lower in HPV-negative than in HPV-positive disease. In Argiris et al. (2014), the objective response rate was 19% for HPV-negative versus 55% for HPV-positive tumors, and median survival was 6.7 versus 12.9 months. After progression of oropharyngeal cancer, 2-year overall survival was 27.6% for p16-negative versus 54.6% for p16-positive disease. With first-line pembrolizumab in U.S. practice, median real-world overall survival in HPV-negative versus HPV-positive disease was 9 versus 20 months on monotherapy and 7 versus 15 months with chemotherapy. ASCO states that current data “do not support changing recommendations” for anti-PD-1 therapy “with regard to the HPV status.”

Source: [Argiris et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4071756/); [Fakhry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4195851/); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.7-4"></a>

###### Summary: options after progression and for locoregional recurrence

The FDA states that approved therapies after platinum-based chemotherapy are associated with an overall response rate of around 20% or less. On November 5, 2026, amivantamab and hyaluronidase-lpuj received accelerated approval after progression on platinum-based chemotherapy and an anti-PD-(L)1 antibody, excluding HPV-associated oropharyngeal squamous cell carcinoma, based on an overall response rate of 42% in the 102-participant primary efficacy population of OrigAMI-4, a multicenter, open-label, multi-cohort trial. Conventional salvage regimens yield response rates of 21% to 69%, median progression-free survival of 2.9 to 5.5 months, and median overall survival of 6.3 to 13.3 months, and a review states that there is “no clear standard of care choice in second-line treatment”. For locoregional recurrence after prior radiation, reirradiation with intensity-modulated radiotherapy had pooled late grade ≥3 and grade 5 toxicity rates of 26% and 3.1%, and postoperative reirradiation with chemotherapy after salvage surgery improved disease-free survival without a significant effect on overall survival.

Source: [FDA press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma); [FDA (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and); [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf); [Abraham et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12691436/); [Lee et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32437021/); [Janot et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18936479/)

<a id="topic-2.2.2.1.7-5"></a>

###### Response rates with pembrolizumab monotherapy

> “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.7-6"></a>

###### Objective response in KEYNOTE-048 at 4-year follow-up

> “Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations”
> “The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population”
> “The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.7-7"></a>

###### Long-term survival plateau in KEYNOTE-048

> “A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone. For patients receiving pembrolizumab-chemotherapy, a survival plateau at approximately 30% was observed for the PD-L1 CPS ≥ 20 population and at approximately 20% for the CPS ≥ 1 and total populations.”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.7-8"></a>

###### Duration of pembrolizumab exposure in KEYNOTE-048

> “The median duration of exposure to KEYTRUDA was 3.5 months (range: 1 day to 24.2 months) in the KEYTRUDA single agent arm and was 5.8 months (range: 3 days to 24.2 months) in the combination arm.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.7-9"></a>

###### Treatment-related adverse events with pembrolizumab plus chemotherapy

> “Any-grade treatment-related AEs occurred in 58.3% (n = 175) of patients in the pembrolizumab-alone group, 95.7% (n = 264) in the pembrolizumab-chemotherapy group, and 96.9% (n = 278) in the cetuximab-chemotherapy group”
> “Grade ≥ 3 treatment-related AEs were reported in 17.0% (n = 51), 71.7% (n = 198), and 69.3% (n = 199) of patients, respectively”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.7-10"></a>

###### Fluorouracil administration and toxicity

> “However, FU is associated with potential challenges (continuous 4-day infusion, high administration costs, and cardiovascular and gastrointestinal toxicities), creating a clinical need for alternative chemotherapy combinations.”

Source: [Dzienis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11361359/)

<a id="topic-2.2.2.1.7-11"></a>

###### Cardiac deaths with cetuximab plus platinum and fluorouracil

> “In EXTREME, fatal cardiac disorders and/or sudden death occurred in 3% of 219 patients treated with a cetuximab product in combination with platinum-based therapy and fluorouracil.”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.2.2.1.7-12"></a>

###### HPV-negative disease: response and survival with first-line chemotherapy

> “The objective response rate was 55% for HPV-positive versus 19% for HPV-negative (P = 0.022), and 50% for p16-positive versus 19% for p16-negative (P = 0.057).”
> “The median survival was 12.9 versus 6.7 months for HPV-positive versus HPV-negative patients (P = 0.014), and 11.9 versus 6.7 months for p16-positive versus p16-negative patients (P = 0.027).”

Source: [Argiris et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4071756/)

<a id="topic-2.2.2.1.7-13"></a>

###### HPV-negative disease: survival after progression of oropharyngeal cancer

> “patients with p16-positive OPC had significantly improved survival rates compared with p16-negative patients (2-year OS, 54.6% v 27.6%; median, 2.6 v 0.8 years; P < .001).”

Source: [Fakhry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4195851/)

<a id="topic-2.2.2.1.7-14"></a>

###### HPV-negative disease: real-world survival with first-line pembrolizumab

> “Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors”
> “Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

<a id="topic-2.2.2.1.7-15"></a>

###### Prognosis and later-line options before immunotherapy

> “The prognosis of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains poor, with a guarded median overall survival (OS) ranging from 10 months to 14 months”
> “Upon progression, the only treatment option was single-agent chemotherapy, with limited response rates and a median survival of 6 months”

Source: [Llop et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625818/)

<a id="topic-2.2.2.1.7-16"></a>

###### Few effective treatment options

> “There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma.”

Source: [Cohen et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30509740/)

<a id="topic-2.2.2.1.7-17"></a>

###### Unmet need stated by the FDA

> “HNSCC is an aggressive, life-threatening disease for which there is a high unmet need for effective therapies.”
> “a disease where treatment options have historically been limited and outcomes remain poor”

Source: [FDA press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma)

<a id="topic-2.2.2.1.7-18"></a>

###### Unmet need after immune checkpoint inhibitor failure

> “The challenge of R/M HNSCC after immune checkpoint inhibitor (ICI) failure represents one of the most pressing unmet needs in oncology.”
> “Between 60 and 80% of patients develop resistance, and historical salvage regimens like cytotoxic chemotherapy or chemotherapy plus cetuximab rarely extend median overall survival (mOS) beyond one year.”

Source: [Abraham et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12691436/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: target population

The Breakthrough Therapy Designation covers ficerafusp alfa with pembrolizumab “for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.” The pivotal FORTIFI-HN01 trial (NCT06788990) enrolls recurrent or metastatic HNSCC with a primary tumor in the “oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC)”; paranasal sinus and nasopharyngeal primaries are excluded. The EU trial record requires “documentation of HPV-negative disease per central testing performed if presenting with OPSCC”, and lists the development of an HPV DNA assay among the sponsor's delegated duties. HPV status is therefore established by testing only for oropharyngeal primaries; Bicara states that HPV testing is “typically only being conducted in tumors originating from the oropharynx”, and the College of American Pathologists recommends against routine HR-HPV testing of primary oral cavity, laryngeal, nasopharyngeal, and hypopharyngeal carcinomas for prognostic purposes. Participants must have “PD-L1 CPS ≥1”, which the EU record specifies as “PD-L1 immunohistochemistry [IHC] via 22C3” in participants eligible “to receive pembrolizumab as frontline monotherapy”. Other criteria are no prior systemic therapy in the recurrent or metastatic setting, systemic therapy for locoregionally advanced disease completed more than 6 months earlier, no prior anti-EGFR antibody outside radiosensitizing or multimodal treatment, no immune checkpoint inhibitor within 6 months, measurable disease by RECIST 1.1, ECOG performance status 0 or 1, and no higher risk of bleeding.

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted); [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990); [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

<a id="topic-2.2.2.2-2"></a>

###### Summary: position relative to current first-line therapy

Ficerafusp alfa would be added to pembrolizumab in first-line treatment, the setting in which pembrolizumab monotherapy (CPS ≥1) and pembrolizumab with platinum and fluorouracil are FDA approved, offered by ASCO with a strong recommendation for CPS ≥1, and listed by NCCN as preferred first-line options. The intended population overlaps the pembrolizumab monotherapy label population, which requires CPS ≥1 by an FDA-authorized test. Hanna et al. state that the combination “could provide a chemotherapy-free regimen”. Bicara reports a “two-to-three-fold increase in median OS” relative to pembrolizumab monotherapy or pembrolizumab with chemotherapy, and states that “No head-to-head studies have been conducted, and cross-trial comparisons may not be reliable”. The available results for ficerafusp alfa are from a single-arm phase 1b trial; topline results of the FORTIFI-HN01 interim analysis are expected in mid-2027, with a potential U.S. launch in 2028.

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328); [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results); [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.2.2.2-3"></a>

###### Summary: anticipated use and care setting

Bicara estimates about 50,000 HPV-negative patients newly diagnosed each year in the United States, EU5, and Japan, about 18,000 of them in the United States, and states that 80% of recurrent or metastatic HNSCC is HPV-negative. In KEYNOTE-048, 85% of tumors had CPS ≥1; among U.S. real-world first-line pembrolizumab recipients with a CPS result (352 participants, 54.5% of the cohort), 83.8% had CPS ≥1. In a U.S. nationwide database drawn primarily from community practices, 32.7% of 2,207 participants with recurrent or metastatic HNSCC received PD-L1 testing before first-line therapy and 50.0% were never tested. In the phase 1b trial, ficerafusp alfa 1,500 mg was given intravenously on days 1, 8, and 15 of 21-day cycles with pembrolizumab 200 mg on day 1; the protocol specifies a 120-minute infusion, extendable to 4 hours, and observation with vital-sign monitoring for 2 hours after the first 2 doses. Bicara is developing a less frequent dosing regimen. Among U.S. real-world first-line pembrolizumab recipients, 583 (90.2%) were treated in community practices and 57 (8.8%) in academic practices.

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.2.2.2-4"></a>

###### Target population named in the Breakthrough Therapy Designation

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

<a id="topic-2.2.2.2-5"></a>

###### Intended first-line use in combination with pembrolizumab

> “We are currently conducting a global, randomized, double-blind, Phase 2/3 FORTIFI-HN01 pivotal trial evaluating 1500mg dosed once weekly, or QW, of ficerafusp alfa in combination with pembrolizumab in first-line, or 1L, recurrent/metastatic, or R/M, human papillomavirus infection, or HPV, -negative head and neck squamous cell carcinoma, or HNSCC, whose tumors express programmed death-ligand 1 with combined positive score, or CPS, of ≥1.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.2.2.2-6"></a>

###### Company estimate of the target population

| Population | Company estimate |
| --- | --- |
| HPV-negative patients newly diagnosed each year in the United States, EU5, and Japan | “~50K” |
| Of those, patients in the United States | “~18K” |

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.2.2.2-7"></a>

###### Share of recurrent or metastatic disease that is HPV-negative

> “An estimated 80% of cases of R/M HNSCC are HPV-negative, with testing for HPV status typically only being conducted in tumors originating from the oropharynx.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.2.2.2-8"></a>

###### Positioning relative to pembrolizumab-based standard of care

> “In total, ficerafusp alfa 1500mg QW in combination with pembrolizumab has demonstrated a two-to-three-fold increase in median OS as compared to both pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy, which in total represent current standard of care for HPV-negative HNSCC patients.”
> “No head-to-head studies have been conducted, and cross-trial comparisons may not be reliable due to differences in molecule composition, trial design, and patient population and characteristics.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.2.2.2-9"></a>

###### Proposed chemotherapy-free first-line regimen

> “Overall, these results suggest that ficerafusp alfa plus pembrolizumab could provide a chemotherapy-free regimen for patients with R/M HNSCC, including those with symptomatic locoregional disease in whom a rapid and durable treatment response would be beneficial.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.2-10"></a>

###### Company statement on market entry

> “aiming for ficerafusp alfa to enter the market with a competitive profile that gives physicians, patients, and payers a clear reason to choose it.”

Source: [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)

<a id="topic-2.2.2.2-11"></a>

###### Weekly intravenous administration with pembrolizumab every 3 weeks

> “Eligible patients received pembrolizumab 200 mg intravenously (IV) on day 1 and ficerafusp alfa 1,500 mg IV on days 1, 8, and 15 in 21-day cycles until disease progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of consent.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.2-12"></a>

###### Infusion duration and post-infusion observation in the phase 1b protocol

> “Pembrolizumab will be administered using a 30-minute IV infusion.”
> “BCA101 will be administered once a week (or once every other week, according to the assigned cohort) via IV infusion over 120 minutes. BCA101 infusions can be extended to up to 4 hours if clinically indicated.”
> “Subjects should be closely observed and vital signs should be monitored for 2 hours after their first 2 doses of combination therapy”

Source: [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf)

<a id="topic-2.2.2.2-13"></a>

###### Less frequent dosing under evaluation for patients and providers

> “which supported our plans to develop an alternate dosing regimen to expand optionality for patients and providers.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

> “Enhance convenience and patient flexibility by offering less-frequent dosing option in combination with pembrolizumab”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.2.2.2-14"></a>

###### Practice setting of first-line pembrolizumab in U.S. real-world data

| Practice type of individuals receiving first-line pembrolizumab | All, n (%) | Monotherapy, n (%) | With chemotherapy, n (%) |
| --- | --- | --- | --- |
| Community | “583 (90.2)” | “384 (89.1)” | “199 (92.6)” |
| Academic | “57 (8.8)” | “43 (10.0)” | “14 (6.5)” |

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### HPV status: response at 1500 mg weekly in the phase 1b cohort

> “In the HPV-negative subgroup (n = 28), the confirmed ORR was 54% (n = 15; 95% CI, 34 to 73), including six patients (21%) with CR”
> “In the HPV-positive subgroup (n = 11), the confirmed ORR was 27% (n = 3; 95% CI, 6 to 61), including two patients (18%) with CR; the CBR was 55% (n = 6; 95% CI, 23 to 83).”
> “Median time to response was 1.4 months (95% CI, 1.4 to 4.7) in the HPV-negative subgroup and 4.1 months (95% CI, 1.3 to 12.0) in the HPV-positive subgroup.”
> “Notably, the ORR and CBR were higher in the HPV-negative versus HPV-positive subgroup.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-2"></a>

###### HPV status: progression-free and overall survival at 1500 mg weekly

> “In the HPV-negative and HPV-positive subgroups, median (95% CI) PFS was 9.9 (4.4 to 22.7) and 2.0 (1.0 to 10.0) months, and 12-month PFS rates (95% CI) were 48.0% (28.9 to 67.1) and 20.8% (0 to 46.3), respectively”
> “Median OS (95% CI) in these subgroups was 21.3 (9.9 to NE) and 16.4 (2.6 to 25.7) months, respectively”
> “subsequent OS assessment in April 2025 showed 24-month OS rates in the HPV-negative and HPV-positive subgroups of 46% (95% CI, 23 to 65) and 27% (95% CI, 1.0 to 53.6), respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-3"></a>

###### HPV status at an earlier data cut of the same cohort

> “Among the EE pts, the ORR was 54% (21/39; 95% CI: 37–70) in the overall cohort and 64% (18/28; 95% CI: 44–81) in HPV-negative pts.”

Source: [Chung et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6017)

<a id="topic-2.2.2.3-4"></a>

###### HPV-positive tumors by smoking history

> “In HPV-positive patients classified as smokers (>10 pack-year smoking history; n = 4) or nonsmokers (n = 7), ORR was 75% and 0%, and CBR was 100% and 29%, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-5"></a>

###### PD-L1 CPS 1-19 versus 20 or greater at 1500 mg weekly

> “Of patients in the HPV-negative subgroup who had a CPS of 1-19 (n = 13) or ≥20 (n = 15), confirmed ORRs were 54% (95% CI, 25 to 81) and 53% (95% CI, 27 to 79), respectively; three additional patients with CPS ≥20 had an unconfirmed response.”
> “In subgroups with CPS 1-19 (n = 19) or ≥20 (n = 20), median (95% CI) PFS was 7.4 (2.7 to NE) and 13.4 (2.8 to 23.2) months, and median OS was 22.0 (7.4 to NE) and 20.6 (6.8 to NE) months, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-6"></a>

###### Locoregional recurrence, tumor burden, and performance status at 1500 mg weekly

> “Within the HPV-negative subgroup, responses occurred in 15 of 21 patients (71%) with locoregionally recurrent disease (with or without distant metastases) and 7 of 14 patients (50%) with baseline sum of target lesions >50 mm.”
> “In patients with ECOG PS 0 (n = 15) or 1 (n = 24), median PFS was 6.9 (2.7 to NE) and 13.4 (4.2 to 26.4) months, and median OS was 20.6 (7.7 to NE) and 26.4 (6.8 to NE) months, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-7"></a>

###### Confirmed response by CPS, tumor burden, and disease extent across the three dose cohorts

| Subgroup, % (n/N) | 750 mg weekly (n=30) | 1500 mg weekly (n=28) | 2000 mg every 2 weeks (n=27) |
| --- | --- | --- | --- |
| CPS 1-19 | “73 (8/11)” | “54 (7/13)” | “57 (8/14)” |
| CPS 20 or greater | “47 (9/19)” | “53 (8/15)” | “38 (5/13)” |
| Sum of target lesion diameters 50 mm or less | “55 (11/20)” | “53 (8/15)” | “53 (9/17)” |
| Sum of target lesion diameters greater than 50 mm | “60 (6/10)” | “54 (7/13)” | “40 (4/10)” |
| Sum of target lesion diameters greater than 70 mm | “50 (2/4)” | “43 (3/7)” | “33 (2/6)” |
| Locoregional disease only | “38 (6/16)” | “62 (5/8)” | “50 (7/14)” |
| Distant metastatic disease only | “100 (5/5)” | “29 (2/7)” | “40 (2/5)” |
| Locoregional and distant metastatic disease | “67 (6/9)” | “62 (8/13)” | “50 (4/8)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-2.2.2.3-8"></a>

###### Dose cohort: response depth and progression-free survival

| Dose cohort | Confirmed ORR (95% CI) | Complete response | Responders with deep response | Median PFS (95% CI), months |
| --- | --- | --- | --- | --- |
| 750 mg weekly | “57% (37%-74%)” | “13%” | “47% (8/17)” | “6.9 (4.6-NE)” |
| 1500 mg weekly | “54% (34%-72%)” | “25%” | “80% (12/15)” | “9.9 (4.4-22.7)” |
| 2000 mg every 2 weeks | “48% (29%-68%)” | “30%” | “77% (10/13)” | “12.7 (4.9-NE)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “ORRs were comparable across all three evaluated dose levels and responses occurred rapidly, with higher dose intensities driving maximal tumor shrinkage”
> “A clear dose-response relationship was observed; escalation from 750 mg (median PFS 6.9 months) to the 1500 mg (median PFS 9.9 months) and 2000 mg Q2W (median PFS 12.7 months) cohorts illustrates the clinical value of optimized TGF-β neutralization and sustained disease control across varying doses and schedules”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-2.2.2.3-9"></a>

###### Dose cohort: 1500 mg versus 750 mg weekly at the December 2025 data cut

> “Improved outcomes were observed in the 1500 mg vs 750 mg cohort, including deep responses (≥80% tumor shrinkage in 80% vs 47% of responders) and mPFS (9.9 mo vs 6.9 mo), along with increased markers of TGF-β inhibition and tumor penetration in paired biopsies, and increased pro-inflammatory cytokines in blood (Table).”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

<a id="topic-2.2.2.3-10"></a>

###### Pembrolizumab monotherapy in KEYNOTE-048 by PD-L1 CPS

> “The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994”
> “The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.3-11"></a>

###### Pembrolizumab in KEYNOTE-048: CPS 1-19 and CPS less than 1 subgroups

> “For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 subgroup (hazard ratio [HR], 1.51 [95% CI, 0.96 to 2.37]) and 10.8 versus 10.1 months in the CPS 1-19 subgroup (HR, 0.86 [95% CI, 0.66 to 1.12]).”
> “Increased efficacy of pembrolizumab or pembrolizumab-chemotherapy was observed with increasing PD-L1 expression.”

Source: [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

<a id="topic-2.2.2.3-12"></a>

###### Pembrolizumab in KEYNOTE-048: other subgroups and HPV status

> “In subgroup analyses, HRs generally favored pembrolizumab alone except for recurrent-only disease (locally recurrent disease and disease that spread to cervical lymph nodes”
> “including in patients with poor prognostic markers such as smoking history and HPV-negative oropharyngeal cancer.”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

> “HPV status according to p16 IHC (positive or negative)”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.3-13"></a>

###### Real-world first-line pembrolizumab by HPV status and primary site

> “Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors; 17 months for those with an ECOG PS of 0–1 versus 6 months for those with an ECOG PS of 2–4; and 13 months for those with oropharyngeal tumors versus 9 months for those with tumors of the larynx, 5 months for those with oral cavity tumors, and 6 months for individuals with tumors of the hypopharynx”
> “Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

Additional sources: [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/); [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Prophylaxis and treatment of acneiform dermatitis in the phase 1b cohort

> “Topical steroids and/or antibiotics were recommended as prophylaxis or treatment for acneiform dermatitis.”
> “Ficerafusp alfa was interrupted because of dermatologic TRAEs in eight patients (19%). Supportive care administered by investigators included topical steroid and antibiotics. No patient discontinued treatment because of dermatitis acneiform or rash TRAEs.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.4-2"></a>

###### Protocol prophylactic skin measures and suggested treatment of rash

> “Prophylactic measures may include but are not limited to: using sunscreen, limiting sun exposure, avoiding hot water/alcohol-based cosmetics that can produce dry skin, using bath oils to enhance skin hydration, using alcohol-free moisturizing creams frequently, using tocopherol oil or gel, avoiding tight shoes to prevent friction/pressure on the nail fold, avoiding excessive beard growth, shaving with regular shaving razor/sharp multiblade, using pre-shaving cream emollients and moisturizing aftershave, avoiding electric shaver.”
> “Antibiotics: clindamycin 1% gel, erythromycin 3% gel/cream, metronidazole 0.75%–1% cream/gel, twice/day until regression to Grade 1 (avoid benzoyl peroxide products).”
> “Antibiotics: minocycline 100 mg orally once/day, doxycycline 100 mg orally once/day for ≥4 weeks until the rash is symptomatic”

Source: [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf)

<a id="topic-2.2.2.4-3"></a>

###### Company description of rash management

> “It is mechanistically related to anti-EGFR activity and is typically well mitigated by treating physicians with the use of steroids and other topicals.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.2.2.4-4"></a>

###### Premedication and management of infusion-related reactions

> “Mandatory premedication regimen 30 to 60 minutes prior to each BCA101 infusion includes”
> “25-50 mg PO diphenhydramine and”
> “500-650 mg PO paracetamol (acetaminophen) will be given or oral equivalent.”

Source: [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf)

> “The infusion rate of ficerafusp alfa was reduced by 50% for grade 1/2 or nonserious infusion-related reactions (IRRs); ficerafusp alfa was permanently discontinued for grade ≥3 or serious IRRs.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.4-5"></a>

###### Supportive care for anemia

> “Supportive care administered by investigators included iron supplementation and transfusion.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.4-6"></a>

###### Mitigation strategies carried into later trials

> “Safety findings from this phase I/Ib study have informed the design of subsequent studies of ficerafusp alfa and pembrolizumab, including mitigation strategies for AEs of special interest.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.4-7"></a>

###### Multidisciplinary team discussion

> “Ideally the optimal treatment strategy should be discussed in an MDT including not only the treating physicians but all the supportive specialities”

Source: [Keam et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8710460/)

<a id="topic-2.2.2.4-8"></a>

###### HPV testing by primary site

> “For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC.”
> “Unlike the oropharynx, identifying HPV in primary oral cavity, laryngeal, and hypopharyngeal SCCs does not have clear and consistent implications for patient prognosis or patient management”

Source: [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

> “For oropharyngeal cancer, p16 IHC is strongly recommended”
> “For recurrent and/or metastatic SCCHN, tumour PD-L1 expression should be evaluated”

Source: [Keam et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8710460/)

<a id="topic-2.2.2.4-9"></a>

###### PD-L1 testing for pembrolizumab monotherapy

> “as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.4-10"></a>

###### HPV and PD-L1 testing in the pivotal trial

> “Participant has documentation of HPV-negative disease per central testing performed if presenting with OPSCC.”
> “Participant is eligible to receive pembrolizumab as frontline monotherapy with documented tumor PD-L1 CPS ≥1 (PD-L1 immunohistochemistry [IHC] via 22C3).”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-2.2.2.4-11"></a>

###### HPV testing method in the phase 1b protocol

> “Subjects presenting with a history of oropharyngeal cancer, must have results from testing of HPV status, defined as p16 expression by IHC analysis.”
> “Subjects with hypopharynx, larynx and oral cavity cancer are not required to undergo HPV testing by p16 IHC.”

Source: [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Sponsor-stated therapeutic goal

> “Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which we believe will drive the tumor penetration of immune cells that lead to deep and durable responses and an increase in overall survival.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.2.2.7-2"></a>

###### Outcomes at the pivotal dose after 3 years of median follow-up

> “Survival: Median OS of 21.3 months with an estimated 31% of patients alive at 3 years”
> “Response: Confirmed ORR of 54% (CR in 25%) with a rapid median time to response of 1.4 months”
> “Depth and durability: Median DOR of 21.7 months; 80% of responders achieved deep responses, defined as ≥80% tumor shrinkage”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-2.2.2.7-3"></a>

###### Timing of response

> “In HPV-negative patients, 56% of responses occurred by the first imaging assessment (6 weeks after treatment) and four patients converted to CR > 6 months after initiating study treatment.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.7-4"></a>

###### Cross-trial comparison with pembrolizumab monotherapy

> “With the caveats of cross-trial comparisons, the ORR of 54% with ficerafusp alfa plus pembrolizumab in the HPV-negative subgroup compares favorably with the ORR of 19% with pembrolizumab monotherapy in patients with CPS ≥1 in the KEYNOTE-048 phase III trial.”
> “In patients with HPV-negative disease, median OS with ficerafusp alfa plus pembrolizumab was 21.3 months, which compares favorably with real-world data for pembrolizumab monotherapy in this population (median 9 months).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

> “Specifically, three-year follow-up from the 1500mg QW dose cohort showed an estimated OS rate of 31%, approximately doubling the survival rate observed in a retrospective analysis with standard of care pembrolizumab in HPV-negative patients.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.2.2.7-5"></a>

###### Benefit the pivotal trial is designed to confirm

> “FORTIFI-HN01 pivotal trial is designed to confirm this benefit”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
